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Abstract 
The work presented in this thesis has demonstrated that supramolecular synthons can be 
used to make multicomponent crystals, and various synthons can be combined to make 
supermolecules. The synthons can also be used to construct nanoscale assemblies. 
Molecules containing single and multiple hydrogen-bond (HB) and halogen-bond (XB) 
acceptor sites have been synthesized in an effort to carry out supramolecular synthesis in order to 
establish a reliable hierarchy for intermolecular interactions. Pyrazole-based molecules have 
been made, combined with various carboxylic acids, and characterized using infrared (IR) 
spectroscopy to give a success rate of 55-70%. Reactions that gave a positive result were 
converted to solution experiments, and crystals were grown and characterized using single-
crystal X-ray diffraction (XRD). The co-crystals display infinite 1-D chains with the intended 
stoichiometry and structural landscape on 6/6 occasions. The salts, on the other hand, display 
unpredictable stoichiometry and structural landscape on 5/5 occasions. Furthermore, the 
electrostatic charge on the primary hydrogen-bond acceptor, N(pyz), can be altered by adding a 
nitro, R-NO2, covalent handle to the backbone of the pyrazole molecule. Addition of a strongly 
electron withdrawing group significantly lowered the charge on the pyrazole nitrogen atom and, 
in turn, lowered the supramolecular yield to 10%. 
Ditopic molecules containing pyrazole and pyridine on the same molecular backbone 
were synthesized and characterized using 
1
H NMR. The molecules were co-crystallized with 
carboxylic acids, and the resulting solids were characterized using IR spectroscopy. The solids 
could then be classified as co-crystal or salt using specific markers in the IR spectrum. Single-
crystal XRD was used to observe the intermolecular interactions in the co-crystals and salts, and 
the co-crystals were assigned to two groups: Group 1 (2) and Group 2 (2). The salts (4) show 
more unpredictability with stoichiometry and structural landscape. 
 A library of ditopic molecules containing triazole and pyridine acceptor sites were 
synthesized and characterized using 
1
H and 
13
C NMR. The molecules were co-crystallized with 
carboxylic acids and the resulting solids were characterized using IR spectroscopy which 
demonstrated a 100% supramolecular yield whenever a pyridine moiety was present, consistent 
with results from Chapter 3. Single-crystal XRD was used to identify the intermolecular 
  
interactions in the co-crystals (2) and salt (1), and the results show that triazole can compete with 
pyridine for hydrogen bond donors. 
A library of ditopic molecules was also used for halogen-bonding (XB) studies with a 
series of activated iodine and bromine-based donors. The results show that iodine donors have a 
higher success rate range (12.5-75%) compared to bromine donors (16.7-50%) based on results 
obtained from IR spectra. Furthermore, the results from the XRD show that pyrazole nitrogen 
atoms can compete with pyridine for forming XB, and two groups of supramolecular synthons 
were observed. 
Finally, relatively weak non-covalent interactions, HB and XB, can influence the 
assembly of nanoparticles based on IR spectroscopy and TEM images. The assembly of the 
particles is influenced by specific capping ligands, which were synthesized and characterized 
using 
1
H, 
13
C and 
19
F NMR. The results demonstrate that relatively weak non-covalent 
interactions based on HB and XB interactions can influence nanoparticle assembly. 
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used to make multicomponent crystals, and various synthons can be combined to make 
supermolecules. The synthons can also be used to construct nanoscale assemblies. 
Molecules containing single and multiple hydrogen-bond (HB) and halogen-bond (XB) 
acceptor sites have been synthesized in an effort to carry out supramolecular synthesis in order to 
establish a reliable hierarchy for intermolecular interactions. Pyrazole-based molecules have 
been made, combined with various carboxylic acids, and characterized using infrared (IR) 
spectroscopy to give a success rate of 55-70%. Reactions that gave a positive result were 
converted to solution experiments, and crystals were grown and characterized using single-
crystal X-ray diffraction (XRD). The co-crystals display infinite 1-D chains with the intended 
stoichiometry and structural landscape on 6/6 occasions. The salts, on the other hand, display 
unpredictable stoichiometry and structural landscape on 5/5 occasions. Furthermore, the 
electrostatic charge on the primary hydrogen-bond acceptor, N(pyz), can be altered by adding a 
nitro, R-NO2, covalent handle to the backbone of the pyrazole molecule. Addition of a strongly 
electron withdrawing group significantly lowered the charge on the pyrazole nitrogen atom and, 
in turn, lowered the supramolecular yield to 10%. 
Ditopic molecules containing pyrazole and pyridine on the same molecular backbone 
were synthesized and characterized using 
1
H NMR. The molecules were co-crystallized with 
carboxylic acids, and the resulting solids were characterized using IR spectroscopy. The solids 
could then be classified as co-crystal or salt using specific markers in the IR spectrum. Single-
crystal XRD was used to observe the intermolecular interactions in the co-crystals and salts, and 
the co-crystals were assigned to two groups: Group 1 (2) and Group 2 (2). The salts (4) show 
more unpredictability with stoichiometry and structural landscape. 
 A library of ditopic molecules containing triazole and pyridine acceptor sites were 
synthesized and characterized using 
1
H and 
13
C NMR. The molecules were co-crystallized with 
carboxylic acids and the resulting solids were characterized using IR spectroscopy which 
demonstrated a 100% supramolecular yield whenever a pyridine moiety was present, consistent 
with results from Chapter 3. Single-crystal XRD was used to identify the intermolecular 
  
interactions in the co-crystals (2) and salt (1), and the results show that triazole can compete with 
pyridine for hydrogen bond donors. 
A library of ditopic molecules was also used for halogen-bonding (XB) studies with a 
series of activated iodine and bromine-based donors. The results show that iodine donors have a 
higher success rate range (12.5-75%) compared to bromine donors (16.7-50%) based on results 
obtained from IR spectra. Furthermore, the results from the XRD show that pyrazole nitrogen 
atoms can compete with pyridine for forming XB, and two groups of supramolecular synthons 
were observed. 
Finally, relatively weak non-covalent interactions, HB and XB, can influence the 
assembly of nanoparticles based on IR spectroscopy and TEM images. The assembly of the 
particles is influenced by specific capping ligands, which were synthesized and characterized 
using 
1
H, 
13
C and 
19
F NMR. The results demonstrate that relatively weak non-covalent 
interactions based on HB and XB interactions can influence nanoparticle assembly. 
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Introduction Chapter 1 - 
 1.1 Supramolecular chemistry 
 
 The term ‘supramolecular chemistry’ is used to describe ‘chemistry beyond the 
molecule’1 and refers to the self-organization2 of small building blocks into larger architectures. 
The term can, in essence, be applied to any system where individual building blocks undergo 
some type of self-assembly to give an entirely new structure, which is different from the 
individual building blocks. 
One of the underlying goals of supramolecular chemistry is to control how to bring 
together two (or more) individual building blocks in a predictable and controllable way. One 
may ask how the inherent ‘selfishness’ of molecules3 may be overcome, when molecules would 
prefer to stick to themselves rather than pair with something else in the same lattice.4 In fact, a 
2013 Scifinder5 search gave 1,900 hits for the term ‘cocrystallization’, and 40,370 for the term 
‘recrystallization’, highlighting the differences and the likelihood of a recrystallization event 
occuring.  
It is important for the supramolecular chemist to recognize the factors controlling the 
process of how molecules recognize and self-assemble with one another. If one can gain control 
over both processes (molecular recognition and self-assembly), then ultimately control over the 
entire system may be attained. Controlling the arrangement of molecules leads to control over 
macroscopic properties of materials.6   
1.1.1 Self-assembly 
What do we mean by self-assembly? There are many examples of systems which undergo 
self-assembly to give larger ‘superstructures’, or ‘supermolecules’, which are different from their 
individual building blocks.7 To help visualize this, three individual units, labeled A, B, and C, 
respectively, self-assemble into one discrete unit, D, shown in Figure 1.1. 
 
Figure 1-1 Self-assembly of three units into one. 
2 
 
Structure ‘D’ may have very different properties from either of the individual 
components, or may be similar as far as physical properties are concerned.  
1.1.1.1 Self-assembly using metal ions and organic ligands 
An example of self-assembly using metal ions and organic ligands is the construction of 
molecular cages by Fujita et al.8 who showed that cis-capped Pd(II) metal ions, which act as 90° 
linkers, can spontaneously self-assemble with a pyridine-based ligand to give an octahedral cage 
driven by coordination bonds between metal ions and pyridine ligands, Figure 1.2. 
 
 
Figure 1-2 Self-assembly of Pd(II) and pyridine linker to form a supramolecular cage 
(figure adapted from reference).8 
1.1.1.2 Self-assembly using organic molecules driven by hydrogen bonds 
Hydrogen bonds are useful tools for assembling supramolecular structures because they 
are both strong and directional (in a non-covalent context).9 For example, small molecules 
containing hydrogen bond donors (or acceptors) can be assembled into one-dimensional chains10, 
two-dimensional sheets11, or three-dimensional layered materials12 by forming intermolecular 
hydrogen bonds.  
Hydrogen bonds are not restricted to small molecule assembly; larger molecules, such as 
cavitands13 and porphyrins14 can also be assembled into predictable structures with unique 
properties. For example, Goldberg et al.15 have shown that pyridine···carboxylic acid hydrogen 
bonds are useful for constructing larger architectures. Moreover, molecules containing pendant 
pyridyl groups with tetra-carboxylic acid molecules can be assembled into 2D sheets, Figure 1.3 
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Figure 1-3 Self-assembly of 5,10,15,20-tetra-4-pyridyl porphyrin (TPP) and benzene-1,2,4,5-
tetracarboxylic acid (B4CA) to form a 2D sheet (figure adapted from reference).16 
1.1.2 Molecular recognition 
Molecular recognition is defined as “the energy and information involved in binding 
(with a purpose) and selection of substrate by a receptor (ligands with a purpose)”.1 An 
illustrative example of molecular recognition occurs when a substrate molecule interacts with an 
enzyme to make an enzyme-substrate complex, Figure 1.4. 
 
Figure 1-4 Molecular recognition of a substrate for an enzyme binding pocket. 
 
Molecular recognition occurs frequently between small molecules when given the choice 
between multiple binding sites. For example, molecules with specific hydrogen bond or halogen 
bond acceptor sites can selectively bind to other molecules when a desirable functional group is 
present.17 An example is shown in Figure 1.5, where the carboxylic acid group specifically 
recognizes the amide group and forms a heteromeric dimer, leaving the iodine to recognize and 
form an intermolecular halogen bond to the pyrazine. 
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Figure 1-5 Two molecular recognition events: the carboxylic acid recognizes and binds 
to the amide, followed by iodine interacting with the pyrazine heterocycle (iodine atoms are 
purple; nitrogen atoms are blue; oxygen atoms are red; hydrogen atoms are white).17 
 
 1.2 Crystal Engineering 
Now that we have described two fundamental processes that occur during the recognition 
and assembly of molecules into ordered structures, it is vital to understand the fundamental 
interactions occuring between the molecules, which allows them to assemble in a predictable and 
controllable way. 
Crystal engineering can be thought of as a sub-section of supramolecular chemistry, and 
the field has its roots in the work of Gerhardt Schmidt from the 1950’s and 1960’s.18 The term 
‘crystal engineering’ was first used by Schmidt in 1971 to describe the photodimerization and 
packing modes of primary amides and dichlorophenyl derivatives in the solid state.19 Since then, 
there has been a significant amount of research conducted to understand how to control the 
arrangement of molecules in the solid state to achieve the desired supramolecular outcome, or 
crystal structure.20   
So, why is all this important? Control over the molecular arrangement, and hence the 
crystal structure, ultimately will give a better handle on the physical properties of materials, 
Figure 1.6. 
 
Figure 1-6 A simple flowchart highlighting the importance of crystal engineering. 
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 1.3 The tools of crystal engineering 
1.3.1 Hydrogen bonds 
Hydrogen bonds are common ‘non-covalent’ interactions used not only in crystal 
engineering,21 but also in biology. Hydrogen bonds are responsible for joining strands of DNA 
through base-pair complementarity. The four base pairs (and their corresponding hydrogen 
bonds, denoted as dotted lines) are shown below, Figure 1.7. 
 
Figure 1-7 Base pairs of DNA with hydrogen bonds shown as dashed lines. T = 
Thymine; A = Adenine; C = Cytosine; G = Guanine. 
 
Larger architectures based on hydrogen bonds can also be made. For example, Rebek et 
al.22 have shown that cavitands, ‘bowl’ shaped molecules, can be assembled using 
complementary hydrogen bonds between ‘bowls’ to make ‘capsules’. Furthermore, the ‘bowl’ 
can be tuned to accommodate a variety of guests23 and cavitand ‘bowls’ have recently 
demonstrated the ability to detect small molecules in human urine.24 
 
1.3.2 Halogen bonds 
Although halogen bonding (XB) is still a relatively new area in crystal engineering, it has 
gained a tremendous amount of attention in the past decade. The number of Scifinder hits 
illustrates that point, where a Scifinder search using the phrase “halogen bonding” doubled from 
2009 to 2011, Figure 1.8. 
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Figure 1-8 Number of Scifinder hits for the term ‘halogen bonding’(figure adapted from 
reference).25 
 
Halogen bonds have been used for the assembly of a number of supramolecular 
structures, ranging from chains26 to liquid crystals27 to pharmaceutical materials.28 For example, 
co-crystals of Itraconazole® show both halogen and hydrogen bonds present at the same time. O-
H···N hydrogen bonds exist between succinic acid and triazole, and C-Cl···O halogen bonds 
exist between dichlorophenyl and triazolone groups,29 Figure 1.9. 
 
Figure 1-9 Combination of hydrogen and halogen bonds in the Itraconazole:succinic acid (2:1) 
co-crystal. 
1.3.3 Supramolecular synthons 
Supramolecular synthons are defined as “structural units within supermolecules which 
can be formed and/or assembled by known or conceivable synthetic operations using 
intermolecular interactions”30. Synthons can be grouped into different classes, depending on if 
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the interaction is between the same (homomeric) or different (heteromeric) functional groups, 
Figure 1.10. 
 
Figure 1-10 Examples of synthons. (A) Homomeric acid···acid. (B) Heteromeric 
acid···pyridine. 
 
Synthons play an important role in crystal engineering, as they represent the ‘glue’ that 
holds small (and large) molecules together and allows molecules to communicate with each 
other. Therefore, a thorough understanding of the nature and binding preferences of any given 
synthon may allow the crystal engineer to design molecular assemblies in a predictable way.31  
1.3.4 Graph set notation 
Graph-set notation was first introduced by Etter et al.32 in the early 1990’s in an effort to 
understand the patterns of hydrogen bonding in organic solids. The notation is based on the 
observed patterns from the crystal structure. The graph set notation goes as follows: 
  
 (n) 
where G is the pattern designator, n is the degree, a is number of acceptors, and d is number of 
donors. The pattern designator, G, can be either S (for intramolecular bonds), C (for infinite 
chains), R (for intermolecular rings), or D (for non-cyclic dimers and other finite structures). As 
an example, take the benzoic acid dimer in Figure 1.9. The acid dimer makes a ring, so we would 
designate that as R. The ring has two hydrogen bond donors, two hydrogen bond acceptors, and 
contains eight total atoms in the ring. Therefore, the graph-set notation would be written as 
  
 (8), Figure 1.11. 
 
Figure 1-11   
 (8) graph set notation for a benzoic acid dimer. 
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Graph set notation is useful for decoding hydrogen bond preferences in the organic solid 
state33, since there can be many options available for small molecules to choose from. 
 1.4 Multicomponent crystals (co-crystals) 
Multicomponent crystals, also called ‘co-crystals’, are defined as “structurally 
homogenous crystalline materials that contain two or more neutral building blocks that are 
solids under ambient conditions and are present in definite stoichiometric amounts”.34  
How do you make a co-crystal? The most common method of making co-crystals is using 
solution-based methods, where a suitable solvent is chosen (which gives moderate to good 
solubility of both components), the components are dissolved in the solvent (usually with 
heating), and allowed to slowly evaporate under ambient conditions. Other methods exist, such 
as solid-state grinding35 and melting36, and recently Boese et al.37 have shown low-temperature 
co-crystallization with acetylene. 
How do we overcome the natural tendency of molecules to‘re-crystallize’ instead of ‘co-
crystallize’, Figure 1.12? 
 
Figure 1-12 Two possible outcomes from slow evaporation of a saturated solution of two 
molecular species, re-crystallization or co-crystallization. 
 
One way to overcome the problem of re-crystallization is to understand the nature of 
intermolecular interactions, or how molecules can bind to one another in a predictable and 
controllable ways. This may be accomplished using a few strategies. First, the electrostatics of 
any molecule can be fine-tuned to make intermolecular interactions more favorable (or less 
favorable) by adding specific covalent handles. For example, the charge on a nitrogen atom 
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acceptor site can be lowered by adding a nitro electron-withdrawing group, R-NO2; the opposite 
can happen by adding methyl groups, which are electron-donating. Second, in order for a co-
crystal to preferentially form, the heteromeric material should have stronger intermolecular 
interactions than either of the homomeric starting materials.21 
1.4.1 Examples of multicomponent crystals (co-crystals) 
Some examples of two-component (binary) crystals which give 0-D motifs will be 
addressed in the following examples. First, a 1:1 co-crystal between 4-nitrobenzoic acid and 3-
(dimethylamino)benzoic acid38 displays the homomeric acid···acid synthon driven by O-H···O 
hydrogen bonds, Figure 1.13. 
 
Figure 1-13 Example of a homomeric synthon.38 
 
In some cases, depending on which functional groups are present, a heteromeric synthon 
is observed. For example, 3,5-dinitrobezamide forms a heteromeric ‘dimer’ with 4-
(dimethylamino)benzoic acid38, Figure 1.14. 
 
 
Figure 1-14 Example of a heteromeric synthon.38 
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Not only can homomeric and heteromeric synthons be used to build binary co-crystals, 
but both synthons can be combined to build three-component crystals (trimeric 
supermolecules),39 Figure 1.15. 
 
Figure 1-15 Example of a trimeric supermolecule containing acid···amide and 
acid···pyridine heterosynthons.39 
 
1.4.2 Applications of multicomponent crystals 
Multicomponent crystals have gained attention, especially in the pharmaceutical industry, 
where physical properties (e.g. solubility, melting behavior, hygroscopicity) of an active 
pharmaceutical ingredient (API) can, in some cases, be modulated by making a new solid form 
of the drug substance. Common solid forms of API molecules with improved properties include 
co-crystals,40 salts,41 and amorphous materials.42 Only co-crystals containing API will be 
addressed in the following section. 
In 2009, Aakeröy et al.
44
 showed that a poorly water soluble cancer drug, bis-
hexamethylene-4-pyridineacetamide (A), could be co-crystallized with various dicarboxylic acid 
coformers (1,2,3,4,5), Figure 1.16.  
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Figure 1-16 API (A) and co-formers (1,2,3,4,5) used to generate co-crystals.44 
 
The reason for choosing a specific co-former have to do with characteristic functional 
groups which can potentially help improve some physical property of the material it is co-
crystallized with (in this case solubility). Short-chain di-carboxylic acids have high aqueous 
solubility, and therefore make attractive candidates for co-crystallization with something that has 
poor aqueous solubility. 
As anticipated, the structural landscape43 of the crystal displayed primary acid···pyridine 
O-H···N heterosynthons which joined the drug and coformer to give 1-D chains. The chains 
were further linked together by carbonyl C=O···H-N acetamide interactions to give 2-D sheets, 
Figure 1.17. 
 
Figure 1-17 2D sheet generated via O-H···N and C=O···H-N synthons between API and 
diacids.
44
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More importantly, the authors demonstrated the improved aqueous solubility of the new 
co-crystals, which showed an increase (A1, A2, A3) over the drug by itself (A); in two cases 
(A4, A5) the solubility was decreased, Figure 1.18.44 
 
Figure 1-18 Comparison of the solubility of an API (A) with co-crystals A1-A5 (figure 
adapted from reference).
44 
 
Recently, Zaworotko et al.45 improved the aqueous solubility of Meloxicam® by 
synthesizing co-crystals with a variety of co-formers. Meloxicam is a non-steroidal anti-
inflammatory drug (NSAID) used to treat pain which contains a sulfinyl (S=O) group which can 
act as a hydrogen-bond acceptor, Figure 1.19. 
 
 
Figure 1-19 Molecular structure of Meloxicam®. 
 
After making co-crystals with various coformers, the aqueous solubility of the new solid 
forms was studied. Co-crystal 1 (Meloxicam:1-Hydroxy-2-Napthoic acid) shows an 
improvement in dissolution rate (and therefore bioavailability) over pure Meloxicam. The results 
from the formation of co-crystals containing API and co-former show improved aqueous 
solubility. It is therefore important for crystal engineers to understand the nature of 
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intermolecular interactions so, in principle, any drug with poor physical properties may be 
transformed into a new solid form with improved physiochemical properties. 
 
 1.5 Goals 
In order to build multicomponent crystals (co-crystals) in a predictable and controllable 
way, one needs to understand the nature of fundamental interactions occurring between 
molecules. In order to accomplish this goal, the synthetic landscape for non-covalent interactions 
needs to be mapped out. In other words, a reliable hierarchy for intermolecular interactions must 
be established which will allow the crystal engineer to build multicomponent crystals with 
predictable structures and desired functionality. 
As a result, the goals of this thesis are to: 
I. Establish if pyrazole···carboxylic acid heterosynthons can be made and are 
reliable enough for synthesizing co-crystals 
Various pyrazole molecules will be synthesized and combined with a library of 
twenty substituted benzoic acid molecules via melt experiments. The resulting 
solids will be analyzed using IR spectroscopy to determine if a reaction occurred 
or not. For those which gave a positive result, they will be converted to solution 
based experiments in an effort to generate single crystals. The crystal structures 
will then be analyzed to determine any binding preferences and patterns of 
intermolecular bonding observed. 
 
II. Test the binding preferences of hydrogen-bond (HB) and halogen-bond (XB) 
donors with a series of ditopic molecules containing two potential binding 
sites: pyridine/pyrazole and pyridine/triazole 
Ditopic molecules containing both pyridine and pyrazole functional groups will 
be synthesized using Suzuki-Miyaura cross-coupling reactions. The molecules 
will be screened with a library of twenty-one carboxylic acids and fourteen 
halogen-bond (XB) donors. Ditopic pyridine/triazole molecules will be made and 
combined with a library of twenty acids. Reactions which give a positive result 
(based on characteristic stretches and shifts in the IR spectrum) will be converted 
14 
 
to solution based experiments to grow single crystals. The structures will be 
analyzed using X-ray crystallography to search for patterns of intermolecular 
bonding and and bonding preferences. 
 
III. Determine whether hydrogen-bond (HB) and halogen-bond (XB) capping 
ligands can be used to influence nanoparticle assembly 
Nanoparticles will be made and functionalized with hydrogen-bond (HB) and 
halogen-bond (XB) donor and acceptor groups. The particles will be made and 
combined to test the viability of HB and XB to influence the assembly of gold 
nanoparticles. The assemblies will be analyzed using UV-Vis, IR spectroscopy, 
and TEM.  
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Is the pyrazole···carboxylic acid synthon robust enough for Chapter 2 - 
driving co-crystal synthesis? 
2.1 Introduction 
Although crystal structure prediction1 has yet to be realized for even the simplest 
compounds, it is important to study intermolecular interactions in solids and to establish a 
toolbox for building supermolecules.2 Gaining control over the composition and dimensionality 
of supramolecular assemblies3 may allow specific structures to be made4 with predictable 
physical properties.5 Therefore, a careful and thorough understanding of how to assemble small 
molecule ‘building blocks’ is essential for developing the synthesis of functional materials.6 
One common intermolecular interaction used for the assembly of building blocks is the 
hydrogen bond,7 which can be formed between an electropositive hydrogen atom and any 
electronegative element, such as nitrogen, oxygen, or sulfur. A significant number of examples 
of hydrogen bonds found in crystal engineering occur between pyridine and carboxylic acids; a 
2012 CSD search gave over 4560 hits8 of this synthon9.  
The interaction involves a primary O-H···N(py) and, occasionally, a secondary C-H···O 
contact, Figure 2.1.10
,11 
 
 
Figure 2-1 The carboxylic acid···pyridine heterosynthon,   
 (7).   
 
In order to expand the synthetic toolbox, it is important to explore other N heterocycles 
containing both a good hydrogen-bond acceptor site (and hydrogen bond donor site), and within 
this class of compounds pyrazole is particularly intriguing. Found as a backbone of many 
agrichemicals12 and as small molecule enzyme inhibitors,13 pyrazole provides a scaffold for 
exploring such interactions. Since the pKb of the pyridine nitrogen (8.75)
14 is lower than that of 
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the pyrazole nitrogen (11.5)15, it is important to know if the charge on the pyrazole is robust 
enough for driving co-crystal synthesis, Figure 2.2. 
 
 
Figure 2-2  The carboxylic acid···pyrazole heterosynthon,   
 (7). 
 
Despite looking very similar to the pyridine···carboxylic acid synthon, and having 
identical graph set notation,   
 (7)16, there are very few examples that demonstrate pyrazole as an 
attractive site for making co-crystals17 and can act as a suitable hydrogen-bond acceptor site with 
carboxylic acids. Surprisingly, an analysis of the CSD of pyrazole and carboxylic acid structures 
gives only 92 hits. Careful examination reveals that the majority of structures containing 
pyrazole are used as ligands in metal coordination complexes18 and the few structures which do 
not contain a metal show the tendency to form either trimer19 and tetramer20 motifs, as opposed to 
forming dimers in solid-state architectures. This study will address the following questions: 
 
I. Is there a pyrazole···carboxylic acid synthon robust enough for driving co-crystal 
synthesis? Hypothesis: pyrazole will provide a suitable hydrogen-bond acceptor 
site N(pyz) which is strong enough to drive co-crystal synthesis. This will be 
achieved by combining nine pyrazoles with twenty benzoic acid coformers. 
II. Can the electrostatic nature of the pyrazole be altered by adding covalent 
‘handles’ to the molecular backbone which influence the supramolecular yield? 
Hypothesis: the electronic nature of the pyrazole can be changed by adding 
electron donating groups (R-X, X=CH3) and electron withdrawing (R-X, X=Cl, 
Br, I, NO2) substituents to the backbone of the pyrazole and will alter the 
electrostatic nature of the N(pyz) acceptor site. A higher charge should increase 
the supramolecular yield.  
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 2.2 Experimental 
2.2.1 Charge calculations 
Molecular electrostatic potential (MEP) surface charge calculations were performed 
using Spartan (Wavefunction, Inc., Irvine, CA). The molecules were optimized using AM1, with 
the maxima and minima in the electrostatic potential surface (0.002 e/au isosurface) determined 
using a positive point charge in the vacuum as a probe. 
2.2.2 Covalent synthesis 
All chemicals were purchased from Aldrich and used without further purification unless 
otherwise noted. Substituted pyrazoles were synthesized according to published literature 
procedures.21
,22,23 NMR data was recorded on a Bruker 200MHz (unless otherwise noted). Melting 
points were determined on a Fisher-Johns melting point apparatus and are uncorrected. 
2.2.2.1 Synthesis of 4-chloro-1H-pyrazole, 1.Cl 
 
 
To a round-bottom flask, 1H-pyrazole (0.89g, 13.1mmol) and H2O (15ml) were added. 
To this solution, N-chlorosuccinimide (NCS, 1.75g, 13.1mmol) was added and the reaction was 
stirred at room temperature for four hours. The reaction was monitored by 
1
H NMR 
(disappearance of the single C-H proton). Upon completion, CHCl3 was added to the reaction 
mixture to create bilayers. The water layer was washed twice with CHCl3 (15mL), the organic 
extracts were combined, dried over MgSO4, and the solvent was removed under vacuum to yield 
1 as a white solid (0.66g, 49%). Mp: 73-74°C (lit. 75-76°C).21 
1
H NMR (200 MHz, CDCl3)  
ppm: 9.88 (br. s., 1H), 7.65 (s, 2H), Figure A-1.
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2.2.2.2 Synthesis of 4-bromo-1H-pyrazole, 1.Br 
 
To a round-bottom flask, 1H-pyrazole (0.52g, 7.6mmol) and H2O (15mL) were added. To 
this solution, N-bromosuccinimide (NBS, 1.4g, 7.6mmol) was added and 4mL of H2O was used 
to wash the NBS off the sides of the flask. The reaction was stirred at room temperature for four 
hours and monitored by 
1
H NMR (disappearance of the single proton). Upon completion, CHCl3 
was added to the reaction mixture to create bilayers. The water layer was washed twice with 
CHCl3(15mL), the organic extracts were combined, dried over MgSO4, and the solvent was 
removed under vacuum to yield 2 as a white solid (0.84g, 75%). Mp: 89-91°C (lit. 91-92°C).21 
1
H 
NMR (δH; 200MHz, CDCl3) ppm: 7.61 (s, 2H), Figure A-2.  
2.2.2.3 Synthesis of 4-iodo-1H-pyrazole, 1.I 
 
To a round-bottom flask, 1H-pyrazole (0.34g, 5.0mmol) and glacial acetic acid (7.4mL, 
129.4mmol) were added. To this solution, I2 (0.51g, 2.0mmol) was added and the solution turned 
brown. Next, HIO3 (0.18g, 1.0mmol) and H2SO4 (200μL) were added. The mixture was refluxed 
with stirring under argon, and the remaining H2SO4 (100μL) and deionized water (700μL) were 
added. The reaction was kept at 70°C, and the solution turned from pink to colorless after 20 
minutes. Saturated NaHCO3(aq)  (1mL) was then added to the refluxing mixture, which was 
cooled to room temperature. Finally, 20% Na2CO3(aq) was added (10mL additions) until no 
bubbling was observed. CHCl3 was added to create bilayers (20mL). The water layer was washed 
three times with CHCl3 (20mL) and the organic extracts were combined, dried over MgSO4, and 
solvent was removed under vacuum to yield 3 as a white solid (0.70g, 72%). Mp: 104-105°C (lit. 
108°C).22 
1H NMR (δH; 200MHz, CDCl3) ppm: 10.66 (br. s., 1H), 7.66 (s, 2H), Figure A-3. 
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2.2.2.4 Synthesis of 4-chloro-(3,5-dimethyl)-1H-pyrazole, 2.Cl 
 
To a 100mL single-neck round bottom flask, 3,5-dimethyl-1H-pyrazole (0.50g, 5.2mmol) 
and 5.4mL of deionized water were added. A white flocculate was observed, at which point 
glacial acetic acid (0.81mL, 14.2mmol) was added, which dissolved the white flocculate. To the 
clear solution, Clorox® Bleach (15mL) was added. A white cloudiness was observed and the 
mixture was stirred at room temperature for two hours, at which point 3mL of saturated 
Na2CO3(aq) was added to neutralize any remaining acetic acid. Two drops of ammonium 
hydroxide were then added and the flask was placed in the refrigerator. The white solids were 
filtered and washed with cold water twice (5mL) to give 4 as a white solid (0.42g, 62%). Mp: 
106-108°C (lit. 117-118°C).23 
1H NMR (δH; 200MHz, CDCl3) ppm: 2.25 (s, 6H), Figure A-4. 
2.2.2.5 Synthesis of 4-bromo-(3,5-dimethyl)-1H-pyrazole, 2.Br 
 
 
To a 100mL single-neck round bottom flask, 3,5-dimethyl-1H-pyrazole (0.55g, 5.8mmol) 
and 22mL of deionized water were added. The mixture was stirred at room temperature until the 
solids dissolved, at which point Br2 (0.3mL, 5.8mmol) was added slowly while stirring. The 
colorless solution turned brown, and the mixture was then neutralized with NaOH(aq) (4M, 
40mL). Brown solids which precipitated were filtered off, and the filtrate was placed in the 
refrigerator overnight. The filtrate was washed twice with CH2Cl2 (50mL), dried over MgSO4, 
and the solvent was removed under vacuum to give 5 as tan solids (0.38g, 38%). Mp: 116-119°C 
(lit. 122°C).23 
1H NMR (δH; 200MHz, CDCl3) ppm: 2.26 (s, 6H), Figure A-5. 
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2.2.2.6 Synthesis of 4-iodo-(3,5-dimethyl)-1H-pyrazole, 2.I 
 
 
To a 250mL three-neck round bottom flask, 3,5-dimethyl-1H-pyrazole (0.51g, 5.3mmol) 
and Na2CO3 (0.30g, 2.8mmol) were added. The solids were then dissolved in 28.2mL of 
deionized water and the mixture was heated to reflux under dinitrogen. In a separate beaker, KI 
(1.75g, 10.5mmol) and I2 (1.31g, 5.16mmol) were dissolved in 4.5mL of deionized water. The 
KI3 solution was added dropwise to the dimethylpyrazole solution at a rate of one drop every 
fifteen seconds.  After 25 minutes, a fine white flocculate formed, and the remaining KI3 solution 
was added to the mixture. The flask was placed in the refrigerator overnight to help precipitation. 
The next day, a white flocculate was filtered and washed twice with 15mL of ice water. The 
filtered solids were then dissolved in 23mL of CH2Cl2. The organic layer was washed once with 
dilute Na2CO3(aq), the organic layer was separated, dried over MgSO4, and concentrated under 
vacuum to give 6 as a white solid (0.51g, 52%). Mp: 135-136°C. 
1H NMR (δH; 200MHz, 
CDCl3) ppm: 2.27 (s, 6H), Figure A-6. 
2.2.2.7 Synthesis of 4-bromo-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 1.Br:N 
To a vial, 4.3 mg (0.029 mmol) of 4-bromo-1H-pyrazole was added along with 1 mL of 
methanol. To a separate vial, 6.1 mg (0.029 mmol) of 3,5-dinitrobenzoic acid was added along 
with 1 mL of methanol. The two solutions were combined in a vial, covered with parafilm (one 
pinhole), and left for slow evaporation. Colorless prisms were obtained after several days. M.p.: 
135-140°C. 
2.2.2.8 Synthesis of 4-iodo-1H-pyrazole:4-cyanobenzoic acid (1:1), 1.I:H 
To a vial, 15.2 mg (0.078 mmol) of 4-iodo-1H-pyrazole was added along with 0.5 mL of 
methanol. To a separate vial, 11.5 mg (0.078 mmol) of 4-cyanobenzoic acid was added along 
with 0.5 mL of methanol. The vial containing the acid was heated until fully dissolved, then 
added to the solution containing the pyrazole. The vial was covered with parafilm (three 
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pinholes) and left for slow evaporation. Colorless prisms were obtained after several days. M.p.: 
189-190°C. 
2.2.2.9 Synthesis of 4-iodo-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 1.I:N 
To a vial, 12.6 mg (0.065 mmol) of 4-iodo-1H-pyrazole was added along with 0.5 mL of 
methanol. To a separate vial, 13.8 mg (0.065 mmol) of 3,5-dinitrobenzoic  acid was added along 
with 0.5 mL of methanol. The two solutions were combined in a vial, covered with parafilm 
(three pinholes), and left for slow evaporation. Colorless plates were obtained after several days. 
M.p.: 123-125°C. 
2.2.2.10 Synthesis of 4-chloro-3,5-dimethyl-1H-pyrazole:4-hydroxy-3-methoxybenzoic acid 
(1:1), 2.Cl:B  
To a vial, 7.3 mg (0.056 mmol) of 4-chloro-3,5-dimethyl-1H-pyrazole was added along 
with 200 µL of methanol. To a separate vial, 9.6 mg (0.057 mmol) of 4-hydroxy-3-
methoxybenzoic acid was added along with 200 µL of methanol. The two solutions were 
combined in a vial, covered with parafilm (one pinhole), and left for slow evaporation. Colorless 
spheres were obtained after several days. M.p.: 205-209°C. 
 2.2.2.11 Synthesis of 4-chloro-3,5-dimethyl-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 2.Cl:N   
To a vial, 5.3 mg (0.041 mmol) of 4-chloro-3,5-dimethyl-1H-pyrazole was added along 
with 200 µL of methanol. To a separate vial, 8.9 mg (0.042 mmol) of 3,5-dinitrobenzoic acid 
was added along with 200 µL of methanol. The two solutions were combined in a vial, covered 
with parafilm (one pinhole), and left for slow evaporation. Colorless prisms were obtained after 
several days. M.p.: 156-160°C. 
 2.2.2.12 Synthesis of 4-bromo-3,5-dimethyl-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 2.Br:N   
To a vial, 5.7 mg (0.033 mmol) of 4-bromo-3,5-dimethyl-1H-pyrazole was added along 
with 1 mL of methanol. To a separate vial, 7.1 mg (0.033 mmol) of 3,5-dinitrobenzoic acid was 
added along with 1 mL of methanol. The two solutions were combined in a vial, covered with 
parafilm (one pinhole), and left for slow evaporation. Colorless plates were obtained after several 
days. M.p.: 155-158°C. 
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 2.2.2.13 Synthesis of 4-chloro-3,5-dimethlyl-1H-pyrazolium:2,4-dinitrobenzoate:4-chloro-3,5-
dimethlyl-1H-pyrazole (1:1:1), 2.Cl:T 
To a vial, 5.6 mg (0.043 mmol) of 4-chloro-3,5-dimethyl-1H-pyrazole was added along 
with 200µL of methanol. To a separate vial, 9.2 mg (0.043 mmol) of 2,4-dinitrobenzoic acid was 
added along with 200µL of methanol. The two solutions were combined in a vial, covered with 
parafilm (one pinhole), and left for slow evaporation. Colorless plates were obtained after several 
days. M.p. 100-102°C. 
 2.2.2.14 Synthesis of 4-iodo-3,5-dimethlyl-1H-pyrazolium:3,5-dinitrobenzoate (1:1), 2.I:N 
To a vial, 5.4 mg (0.024 mmol) of 4-iodo-3,5-dimethyl-1H-pyrazole was added along 
with 200µL of methanol. To a separate vial, 5.2 mg (0.024 mmol) of 3,5-dinitrobenzoic acid was 
added along with 200µL of methanol. The two solutions were combined in a vial, covered with 
parafilm (one pinhole), and left for slow evaporation. Colorless prisms were obtained after 
several days. M.p. 138-142°C. 
2.2.2.15 Synthesis of 1H-pyrazolium:3,5-dinitrobenzoate:3,5-dinitrobenzoic acid (1:1:1), 
1.H:N  
To a small beaker, 29.1 mg (0.43 mmol) of 1H-pyrazole was added and dissolved in 1 ml 
of absolute ethanol (200 proof). To a separate beaker, 91.4 mg (0.43 mmol) of 3,5-dinitrobenzoic 
acid was added and dissolved in 1 ml of  absolute ethanol (200 proof). The two solutions were 
combined in a beaker, covered with parafilm (five pinholes), and left for slow evaporation. 
Colorless plates were obtained after several days. M.p. 146-148°C. 
 2.2.2.16 Synthesis of 3,5-dimethyl-1H-pyrazolium:3,5-dinitrobenzoate hydrate (1:1:1), 
2.H:N:H2O 
To a small beaker, 27.9 mg (0.29 mmol) of 3,5-dimethyl-1H-pyrazole was added and 
dissolved in 1 ml of absolute ethanol (200 proof). To a separate beaker, 62.3 mg (0.29 mmol) of 
3,5-dinitrobenzoic acid was added and dissolved in 1 ml of absolute ethanol (200 proof). The 
two solutions were combined in a test tube and left for slow evaporation. Colorless prisms were 
obtained after several days. M.p. 120-124°C. 
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2.2.2.17 Synthesis of 1H-pyrazolium:2,6-dichlorobenzoate:2,6-dichlorobenzoic acid (1:1:1), 
1.H:R  
To a test tube, 13.1 mg (0.19 mmol) of 1H-pyrazole was added along with 39.3 mg (0.21 
mmol) of 2,6-dichlorobenzoic acid. The solids were heated using a heat gun until both 
components had melted. The melt was allowed to cool to room temperature, yielding colorless 
plates. M.p.: 71-73°C. 
2.2.3 IR 
Infrared experiments were collected on a Thermo Scientific Nicolet 380 FT-IR using a 
ZnSe crystal. The solids obtained from melt (or solution) experiments were analyzed by placing 
the solid directly on the crystal and performing 32 scans. 
 
 2.3 Results 
2.3.1 MEP surface calculations 
Molecular electrostatic potential (MEP) surface calculations were made in order to rank 
the strengths of the hydrogen bond donor (H) and acceptor (N) sites. Although a low level of 
theory is used (AM1)24, PM3 and DFT (B3LYP/6-311+G** level) calculations were also 
conducted to see if a similar trend in binding site strength site was observed. Previously, Hunter25 
and co-workers26 showed that AM1 works well for calculating electrostatic surface energies for 
small molecules like N-methyl acetamide. 
Table 2.1 Molecular electrostatic surface potential calculations for the various pyrazoles (AM1, 
PM3, DFT). Values given in kJ/mol. 
Molecule AM1 (H) AM1 (N) PM3 (H) PM3 (N) DFT (H) DFT (N) 
1.H 178 -251 156 -307 245 -186 
1.Cl 194 -236 167 -289 269 -159 
1.Br 200 -230 169 -283 273 -160 
1.I 200 -231 161 -282 - - 
1.NO2 254 -260 280 -297 315 -162 
2.H 171 -256 141 -308 226 -195 
2.Cl 188 -238 150 -298 260 -172 
2.Br 193 -239 152 -293 253 -171 
2.I 191 -237 150 -302 - - 
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2.3.2 Covalent synthesis 
Nine pyrazole molecules were synthesized with different covalent substituents on the 
molecular backbone intended to alter the electrostatic potential surface energy of the molecule. 
The nine pyrazole molecules used are shown in Scheme 1. Six of the nine pyrazoles used were 
synthesized according to literature procedures, and the results are summarized in Table 2.1.  
 
 
 
Scheme 1. The nine pyrazole molecules used in this study. 
 
Table 2.2 
1
H NMR data, yields, and melting points for six pyrazoles synthesized. 
Molecule 1H NMR values [Lit. value] Melting point [Lit. value] % Yield 
1.Cl 7.58 (s, 2H, CH) [7.55, s, 2H, CH] 73-74°C [75-76°C]21
 49% 
1.Br 7.61 (s, 2H, CH) [7.53, s, 2H, CH] 89-91°C [91-92°C]21 30% 
1.I 7.65 (s, 2H, CH) [7.64, s, 2H, CH] 104-105°C [108°C]22
 47% 
2.Cl 2.25 (s, 6H, CH3) [2.25, s, 6H, CH3] 106-108°C [117-118°C]23
 62% 
2.Br 2.26 (s, 6H, CH3) [2.26, s, 6H, CH3]
 116-119°C [122°C]23 38% 
2.I 2.27 (s, 6H, CH3) [2.27, s, 6H, CH3]
 135-136°C [Not reported] 52% 
 
2.3.3 Infrared data 
The pyrazole molecules were screened with twenty carboxylic acids of varying pKa 
strength, Table 2. 
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Table 2.3 Table of aromatic carboxylic acids used in the study.  
Label (pKa)27 Benzoic Acid  
A (4.57 +/- 0.10) 4-Hydroxybenzoic acid 
B (4.45 +/- 0.10) 4-Hydroxy-3-methoxy benzoic acid 
C (4.34 +/- 0.10) 3,5-Dimethylbenzoic acid 
D (4.08 +/- 0.10) 3-Hydroxybenzoic acid 
E (4.02 +/- 0.10) 4-Iodobenzoic acid 
F (3.97 +/- 0.10) 4-Chlorobenzoic acid 
G (3.64 +/- 0.10) 3-Cyanobenzoic acid 
H (3.54 +/- 0.10) 4-Cyanobenzoic acid 
I (3.48 +/- 0.10) 3-Nitrobenzoic acid 
J (3.46 +/- 0.10) 3-Bromo-5-iodobenzoic acid 
K (3.42 +/- 0.10) 4-Nitrobenzoic acid 
L (3.27 +/- 0.10) 2-Fluorobenzoic acid 
M (2.97 +/- 0.25) 2-Chlorobenzoic acid 
N (2.77 +/- 0.10) 3,5-Dinitrobenzoic acid 
O (2.34 +/- 0.10) 2,6-Difluorobenzoic acid 
P (2.19 +/- 0.25) 2-Nitrobenzoic acid 
Q (1.93 +/- 0.10) 2-Fluoro-6-iodobenzoic acid 
R (1.69 +/- 0.10) 2,6-Dichlorobenzoic acid 
S (1.60 +/- 0.10) Pentafluorobenzoic acid 
T (1.43 +/- 0.25) 2,4-Dinitrobenzoic acid 
 
The results from the screening experiment are summarized in Table 2.4, and the 
corresponding supramolecular yield (calculated as the number of positive hits) is given in the last 
row. 
 
Table 2.4  Summary of prominent IR stretches (cm
-1
) from the melt experiments between nine 
pyrazoles and twenty carboxylic acids. 
Acids 1.H 1.Cl 1.Br 1.I 1.NO2 2.H 2.Cl 2.Br 2.I 
A - 
2499, 1897, 
1666 
2507, 1874, 
1674 
- - 
2488, 
1855, 1679 
- 
2507, 
1897, 
1691 
- 
B - - - - - 
2496, 
1879, 1667 
2491, 
1878, 1667 
2491, 
1881, 
1671 
2448, 
1870, 
1675 
C - - - - - - 
2452, 
1838, 1671 
- - 
D,E, F - - - - - - - - - 
G - 
2440, 1862, 
1682 
2535, 1865, 
1693 
2535, 
1872, 
1686 
- - - 
2382, 
1870, 
1679 
- 
H - 
2464, 1862, 
1729 
2396, 1865, 
1693 
2469, 
1885, 
1699 
- 
2503, 
1897, 1699 
2553, 
1893, 1687 
2541, 
1889, 
1675 
2357, 
1850, 
1695 
I 
2382, 1883, 
1695 
2436, 1885, 
1702 
2425, 1862, 
1698 
2401, 
1835, 
2491, 
1893, 
2484, 
1891, 1687 
2632, 
1889, 1720 
2448, 
1878, 
2429, 
1889, 
28 
 
1679 1721 1688 1695 
J 
2397, 1928, 
1690 
- - 
2499, 
1867, 
1675 
- 
2350, 
1858, 1704 
2429, 
1850, 1708 
2468, 
1897, 
1708 
2456, 
1862, 
1716 
K - 
2487, 1874, 
1690 
2429, 1854, 
1690 
2417, 
1846, 
1687 
- - - 
2433, 
1893, 
1683 
2429, 
1866, 
1683 
L 
2533, 1912, 
1679 
2433, 1881, 
1694 
2495, 1878, 
1683 
- - 
2476, 
1891, 1695 
2397, 
1881, 1712 
2390, 
1901, 
1720 
2417, 
1893, 
1716 
M 
2517, 1936, 
1679 
2515, 1878, 
1682 
2495, 1881, 
1682 
- - 
2476, 
1904, 1695 
2499,1917, 
1679 
2511, 
1921, 
1679 
2448, 
1885, 
1687 
N 
2436, 1866, 
1702 
2413, 1854, 
1698 
2405, 1823, 
1691 
2413, 
1827, 
1691 
- 
2492, 
1851, 1683 
2519, 
1842, 1701 
2413, 
1889, 
1704 
2433, 
1846, 
1698 
O 
2492, 1932, 
1704 
- - - - 
2521, 
1887, 1720 
- - - 
P 
2448, 1874, 
1702 
2526, 1874, 
1674 
2522, 1885, 
1678 
- - 
2459, 
1842, 1708 
- 
2554, 
1897, 
1699 
2386, 
1901, 
1691 
Q 
2357, 1912, 
1720 
2464, 1893, 
1706 
2491, 1893, 
1702 
2464, 
1885, 
1704 
2546, 
1862, 
1698 
2488, 
1887, 1712 
2483, 
1909, 1712 
2358, 
1893, 
1675 
2452, 
1909, 
1712 
R 
2440, 1885, 
1709 
2483, 1893, 
1709 
2499, 1897, 
1713 
2415, 
1897, 
1704 
- 
2491, 
1885, 1708 
2476, 
1901, 1716 
2483, 
1881, 
1704 
2468, 
1889, 
1708 
S 
2296, 1932, 
1647 
2421, 1909, 
1702 
- - - 
2435, 
1822, 1699 
- - - 
T 
2429, 1866, 
1713 
2425, 1878, 
1706 
2366, 1881, 
1708 
2374, 
1881, 
1709 
- 
2522, 
1893, 1717 
2464, 
1889, 1704 
2456, 
1878, 
1699 
2358, 
1885, 
1704 
Supramolecular 
yield (%) 
11/20 = 
55% 
13/20 = 
65% 
12/20 = 
60% 
12/20 = 
60% 
2/20 = 
10% 
14/20 = 
70% 
11/20 = 
55% 
14/20 = 
70% 
12/20 = 
60% 
 
2.3.4 Crystal structure of 4-bromo-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 1.Br:N 
The crystal structure determination of 1.Br:N shows a co-crystal with the intended 1:1 
stoichiometry. The acidic protons remain on the two unique carboxylic acids as shown by the 
significantly different C=O/C-O(H) bond lengths, 1.219(4)/1.325(4) Å, and 1.219(4)/1.312(4) Å, 
respectively. The driving force for the reaction is the heteromeric O-H···N(pyz)/N-H···O 
synthon, resulting in head-to-head dimers, Figure 2.3.  These dimers are organized into 1-D 
chains via C-Br···O(nitro) halogen bonds; r(C-Br···O) is 3.148 Å and 3.028 Å; C-Br···O angle is 
157° and 154°, respectively.  
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Figure 2-3  Infinite 1-D chain in the crystal structure of 1.Br:N driven by O-H···N(pyz) and N-
H···O synthons. N-O
-
···Br interactions extend the dimers into 1D chains. 
2.3.5 Crystal structure of 4-iodo-1H-pyrazole:4-cyanobenzoic acid (1:1), 1.I:H 
The crystal structure of 1.I:H displays a very similar supermolecule as in 1.Br:N. A 
head-to-head dimer is constructed from neutral O-H···N(pyz)/N-H···O synthons, Figure 2.4.  
The dimers are assembled into infinite 1-D chains by CN···I halogen bonds, where the CN···I 
distance is 3.183 Å with a C-I···N angle of 179°. 
 
 
Figure 2-4 Infinite 1-D chain in the crystal structure of 1.I:H driven by O-H···N(pyz) and N-
H···O synthons. C-N···I interactions extend the dimers into 1-D chains. 
 
 2.3.6 Crystal structure of 4-iodo-1H-pyrazole: 3,5-dinitrobenzoic acid (1:1), 1.I:N 
The crystal structure of 1.I:N also contains 1-D chains where dimer formation occurs via 
O-H···N(pyz) and N-H···O interactions. The dimers are connected into 1-D chains through C-
H···O synthons. The chains are linked together in a stair-step fashion through I···I (type I)28 
halogen bonds, Figure 2.5.  The I···I distance is 3.698 Å and the C-I···I angle is 137°. 
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Figure 2-5 An overview of the 2-D layer in the crystal structure of 1.I:N. 
 2.3.7 Crystal structure of 4-chloro-3,5-dimethyl-1H-pyrazole:4-hydroxy-3-methoxybenzoic 
acid (1:1), 2.Cl:B 
The crystal structure of 2.Cl:B contains head-to-head heterodimers formed via O-
H···N(pyz) and N-H···O synthons, Figure 2.6. The N-H proton is bifurcated between the C=O 
oxygen from one acid and the O-H oxygen from a second symmetry-related neutral acid. The 
synthons combine to form an extended zig-zag chain.  
 
Figure 2-6 Infinite 1-D zig-zag chain in the structure of 2.Cl:B. 
 
 2.3.8 Crystal structure of 4-chloro-3,5-dimethyl-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 
2.Cl:N 
The structure of 2.Cl:N contains neutral heterodimers formed by O-H···N(pyz) and N-
H···O synthons, Figure 2.7.  The dimers extend into 1-D chain via C-Cl···O synthons. The C-
Cl···O distance is 3.065 Å and the C-Cl···O angle is 170°. 
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Figure 2-7 1-D chain of in the structure of 2.Cl:N. 
 2.3.9 Crystal structure of 4-bromo-3,5-dimethyl-1H-pyrazole:3,5-dinitrobenzoic acid (1:1), 
2.Br:N 
In the crystal structure of 2.Br:N, an infinite chain is observed where O-H···N(pyz) and 
N-H···O synthons drive co-crystal formation, Figure 2.8. The C-Br···O
-
 distance is 3.022 Å and 
the C-Br···O
-
 angle is 174°. 
 
Figure 2-8 1-D chain in the crystal structure of 2.Br:N. 
 2.3.10 Crystal structure of 4-chloro-3,5-dimethyl-1H-pyrazolium:2,4-dinitrobenzoate:4-
chloro-3,5-dimethyl-1H-pyrazole (1:1:1), 2.Cl:T 
In the crystal structure 2.Cl:T, proton transfer occurred resulting in salt formation.  Not 
only has the proton been transferred from the acid to the base, an additional neutral pyrazole 
molecule is also included in the lattice, Figure 2.9.  The three building blocks are assembled into 
discrete trimers, driven by N-H···O, N-H···N, and charge-assisted N-H
+
···
-
O synthons. 
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Figure 2-9 A hydrogen-bonded trimer in the crystal structure of 4-chloro-3,5-
dimethylpyrazolium:2,4-dinitrobenzoate:4-chloro-3,5-dimethylpyrazole, 1:1:1, 2.Cl:T. 
 2.3.11 Crystal structure of 4-iodo-3,5-dimethyl-1H-pyrazolium:3,5-dinitrobenzoate (1:1), 
2.I:N 
The reaction between 2.I and N also results in an ionic compound. A combination of 
charge-assisted N-H
+
···
-
O, N-H···O, and N-H···
-
O synthons produce tetramers, Figure 2.10, 
which are connected into a ladder-like motif via  C-I···
-
O interactions, with a C-I···
-
O distance of 
3.089 Å and a  C-I···
-
O angle of 178°. 
 
 
Figure 2-10 Tetramers (subsequently linked into ribbon) formed in the solid product 
resulting from a combination of 2.I and N. 
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 2.3.12 Crystal structure of 1H-pyrazolium:3,5-dinitrobenzoate:3,5-dinitrobenzoic acid (1:1:1), 
1.H:N 
Figure 2.11 depicts a zig-zag chain formed by charge-assisted N-H
+
···
-
O synthons in the 
crystal structure of the ionic compound produced when 1.H was allowed to react with N. The N-
H proton is bifurcated between a C=O oxygen from a second neutral acid and the carboxylate 
oxygen directly involved in the hetero dimer. The second neutral acid also forms an O-H···
-
O 
synthon to complete the structure. 
 
Figure 2-11 A zig-zag chain in the crystal structure of pyrazolium 3,5-dinitrobenzoate 
3,5,-dinitrobenzoic acid (1:1:1), 1.H:N. 
 2.3.13 Crystal structure of 3,5-dimethyl-1H-pyrazolium:3,5-dinitrobenzoate hydrate (1:1), 
2.H:N:H2O  
The proton transfer from N to 2.H produces the only hydrate in this series.  The main 
feature is a trimer involving all three components, Figure 2.12.  The N-H proton interacts directly 
with the oxygen from water to form a N-H···Ow synthon. The O-H(water) ···O(carbonyl) 
synthon completes the trimer. 
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Figure 2-12 A hydrated ion-pair in the crystal structure of pyrazolium:3,5,-
dinitrobenzoate hydrate (1:1), 2.H:N 
 
 2.3.14 Crystal structure of 1H-pyrazolium:2,6-dichlorobenzoate:2,6-dichlorobenzoic acid 
(1:1:1), 1.H:R 
The reaction between 1.H and R also produces an ionic compound where the main 
feature of the crystal structure is a tetramer, Figure 2.13, held together by charge-assisted N-
H
+
···
-
O synthons. 
 
 
Figure 2-13 Discrete tetramers formed in the crystal structure of 1.H:R. 
 
All hydrogen bond geometries are listed in Table 2.5. 
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Table 2.5 Hydrogen bond geometries. 
Structure D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
1.Br:N 
 
N111-H111...O221 
N112-H112...O222 
O211-H211...N121 
O212-H212...N122 
0.87(5) 
0.75(5) 
0.88(5) 
0.89(5) 
2.11(5) 
2.18(5) 
1.80(5) 
1.79(5) 
2.834(4) 
2.828(4) 
2.674(4) 
2.657(4) 
140(4) 
145(5) 
175(5) 
167(5) 
1.I:H 
O(11)-H(11)…N(22) 
N(21)-H(21)…O(12) 
0.96(2) 
0.79(2) 
1.70(2) 
2.16(2) 
2.6521(17) 
2.8225(17) 
171(2) 
141(2) 
1.I:N 
O(11)-H(11)...N(22) 
N(21)-H(21)...O(12) 
O(31)-H(31)...N(42) 
N(41)-H(41)...O(32) 
0.87(2) 
0.78(2) 
0.83(2) 
0.76(2) 
1.75(2) 
2.31(2) 
1.84(2) 
2.28(2) 
2.6225(17) 
2.9250(17) 
2.6671(18) 
2.9050(18) 
177(2) 
136(2) 
176(2) 
140(2) 
2.Cl:B 
 
 
N(11)-H(11)...O(22) 
O(21)-H(21)...N(12) 
O(24)-H(24)...O(22)#1 
0.89(3) 
0.90(3) 
0.84(4) 
2.18(3) 
1.76(3) 
2.01(4) 
2.875(2) 
2.654(2) 
2.636(2) 
136(3) 
174(3) 
131(3) 
2.Cl:N 
 
 
N(11)-H(11)...O(22) 
O(21)-H(21)...N(12) 
0.758(18) 
0.814(18) 
2.619(17) 
1.810(19) 
3.1647(13) 
2.5946(13) 
130.6(16) 
161.6(18) 
2.Br:N 
 
 
N(11)-H(11)...O(22) 
O(21)-H(21)...N(12) 
0.98(5) 
1.28(5) 
2.49(5) 
1.30(5) 
3.180(5) 
2.578(4) 
128(3) 
173(4) 
2.Cl:T 
 
N(11)-H(11)...O(38) 
N(12)-H(12)...N(22) 
N(21)-H(21)...O(37) 
1.15(2) 
0.92(2) 
0.78(3) 
1.41(2) 
1.91(3) 
1.98(3) 
2.541(2) 
2.811(2) 
2.740(2) 
167(2) 
166(2) 
167(3) 
2.I:N 
 
 
N11A H11A O21 
N11B H11B O21 
N12A H12A O23 
N12B H12B O23 
0.88 
0.88 
0.880.88 
1.85 
2.20 
2.191.91 
2.713(6) 3.005(9) 
3.024(6) 2.772(7) 
168.4 
151.1 
158.6 
164.3 
1.H:R 
 
 
N11 H11 O21 
N12 H12 O21 
O31 H31 O22 
 
0.87(4) 
0.92(4) 
0.83(5) 
1.94(4) 
1.78(4) 
1.75(5) 
2.797(4) 
2.650(4) 
2.575(4) 
166(4) 
158(4) 
171(5) 
1.H:N 
N11A2-H11A2...O312 
N12A2-H12A2...O322 
N11B2-H11B2...O312 
N12B2-H12B2...O222 
O211-H211...O311 
O212-H212...O312 
0.88 
0.88 
0.89(4) 
0.83(4) 
0.86(4) 
0.79(4) 
2.30 
2.22 
1.73(4) 
1.99(4) 
1.67(4) 
1.72(4) 
2.843(17) 
3.059(17) 
2.620(3) 
2.741(3) 
2.522(3) 
2.517(3) 
119.7 
160.6 
178(4) 
149(3) 
172(3) 
177(4) 
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2.H:N 
 
N11 H11 O21 
N12 H12 O1W 
O1W H1A O22 
O1W H1B O22 
0.995(17) 
0.967(16) 
0.890(19) 
0.888(18) 
1.595(17) 
1.713(16) 
1.851(19) 
1.880(18) 
2.5747(14) 
2.6490(14) 
2.7390(13) 
2.7681(13) 
167.2(15) 
162.0(15) 
174.9(17) 
178.9(18) 
 
 2.4 Discussion 
 2.4.1 Can the charge on the pyrazole backbone be altered by adding covalent ‘handles’? 
 From the MEP surface charge calculations, all three levels of theory (AM1, PM3, and 
DFT) give a consistent ranking of hydrogen-bond acceptor ability of the N(pyz) site. The most 
significant changes in charge were observed for 4-nitropyrazole, which gave a significantly 
lower charge (-260 kJ/mol) for the N(pyz) acceptor site (and substantial increase in charge for 
the N-H proton, 254 kJ/mol). The charge calculations do not show a significant difference in 
N(pyz) acceptor site strength between the halogen and halogen/methyl substituted pyrazoles. 
When weakly electron withdrawing (and donating) groups were used (R-X, X=Cl, Br, I, CH3) on 
the pyrazole backbone, a charge between -231 kJ/mol to -251 kJ/mol was observed.  
On the other hand, when a strongly electron withdrawing substitutent is added (X=NO2), 
the magnitude of charge on the N(pyz) acceptor site increases to -260 kJ/mol. The result 
demonstrates that even slight covalent alterations to the molecular backbone will have substantial 
consequences on charge of the N(pyz) acceptor site. 
 2.4.2 Do the results from the screening experiment corroborate the charge calculations? 
From the screening experiments between nine pyrazoles and twenty carboxylic acids, the 
results indicate that charge plays an important role in determining supramolecular yield. When 
halogen and methyl covalent handles were added, the charge on the primary hydrogen bond 
acceptor N(pyz) does not change significantly, and the supramolecular yield was 55-70%. When 
a strongly electron withdrawing substituent like nitro (X=NO2) group was added, the negative 
charge increases on the primary hydrogen bond acceptor site, and subsequently lowers the 
supramolecular yield to 10%. The results support the view of hydrogen bonds as primarily 
electrostatic in nature, as changes in the electrostatic charge significantly affect the 
supramolecular yield. 
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 2.4.3 Co-crystals 
Six co-crystals were obtained and all gave the expected stoichiometry (1:1) and the 
intended chemical composition.  As expected, the primary O-H···N(pyz) and secondary N-
H···O=C interactions drive co-crystal formation. It is noteworthy to point out that pKa values of 
the acids play an important role in dictating the outcome. For example, when acids with pKa 
values of 2.77 and greater were used, only co-crystal formation was observed.   
 2.4.4 Salts 
Five salts were obtained which gave unexpected stoichiometry and unpredictable 
structural landscapes. When acids with pKa values of below 2.77 were used, only salt formation 
was observed where the proton from the carboxylic acid was transferred to the nitrogen of the 
base. The salts display unusual structural landscapes, which involve either water molecules or 
neutral acids (and bases) becoming part of the main structure. Of those observed, charge-assisted 
COO
-
···
+
H-N were the most common, followed by N-H···N interactions. 
 2.4.5 Do other nitrogen-based heterocycles display structural unpredictability when proton 
transfer occurs? 
A search of the CSD for pyridinium cations combined with benzoate anions gives 397 
hits, out of which structures containing a water, solvent, neutral acid or neutral base molecule 
totaled 181 (181/397 = 0.455), ~ 46%. This result shows it is not uncommon to observe other 
molecules, including solvent, in the structure when proton transfer processes occur, as observed 
in the salts formed between pyrazole and substituted benzoic acids. This result further shows the 
advantages of co-crystals over salts as far as stoichiometry and composition are concerned.  
 2.4.3 Is the pyrazole···carboxylic acid synthon robust enough for driving co-crystal synthesis? 
Six co-crystals were obtained from solution based experiments from the combination of 
pyrazole and various benzoic acids, and the expected pyrazole···carboxylic acid synthon occurs 
6/6 times (100% supramolecular yield). Great structural consistency was observed in the co-
crystals synthesized in this series, demonstrating the usefulness and robustness of the 
pyrazole···carboxylic acid synthon in forming co-crystals with predictable stoichiometry 
intended chemical composition, and structural landscape29, Figure 2.14. 
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Figure 2-14 Summary of the results obtained from co-crystals and salts. 
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Structural competition between carboxylic acid···pyridine Chapter 3 - 
and carboxylic acid···pyrazole: is there a difference? 
 3.1 Introduction 
In Chapter 2, carboxylic acid···pyrazole interactions were shown to be capable of driving 
co-crystal formation1 and to expand on this work, we wanted to determine what would happen in 
a competitive environment if a second hydrogen-bond acceptor site, pyridine, was added to the 
same molecular backbone. The acid can then choose between two different sites, N(py) or 
N(pyz), Figure 3.1.  
 
Figure 3-1 Two potential binding sites for an incoming carboxylic acid. 
 
The incoming acid can potentially bind to one site or the other (or both), depending on 
both electrostatic charge as well as steric factors. Potential supramolecular interactions between 
the acid and binding sites are shown below, Figure 3.2. 
 
Figure 3-2 Potential supramolecular interactions between acid and N(py) and N(pyz). 
 
When synthesizing co-crystals between carboxylic acids and ditopic molecules (Figure 
3.2) it is important to understand where the acid prefers to bind for stoichiometry purposes and in 
order to predict structure and topology. Balance is exceedingly important when designing new 
solid forms2 of materials, like pharmaceutical drugs, where multiple binding sites frequently exist 
on the active pharmaceutical ingredient for a coformer to bind with. Whether a co-crystal or salt3 
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is obtained, the outcome can have drastic consequences for the physical properties of the solid 
material, from differences in melting behavior to differences in solubility.4 An illustrative 
example of a pharmaceutical drug with multiple binding sites is Nexium,5 Figure 3.3. 
 
Figure 3-3 Nexium© and potential binding sites for hydrogen bond donors. 
 
This drug contains at least two potential hydrogen-bond acceptor target sites for forming 
a hydrogen bond with a carboxylic acid-based coformer. Therefore, it is important to understand 
binding preferences for stoichiometry purposes during scale-up processes and for control of the 
structural landscape in crystals.6 
To examine the binding preferences of carboxylic acids with pyridine and pyrazole, when 
both functional groups are present on the same molecular backbone, ditopic molecules 
containing both functional groups were synthesized, Figure 3.4. 
  
 
Figure 3-4 Library of isomeric ditopic molecules 2, 3, and 4. The molecules have been 
named based on the position of the pyridine nitrogen atom. 
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Although work has been done on metal coordination chemistry of 4 using cobalt and 
zinc,7 there is no CSD data available which examines the binding preferences of carboxylic acids 
for N(py) or N(pyz) when present together.  
To address the competition between N(py) and N(pyz) in the presence of carboxylic 
acids, charge calculations were performed on the molecules to establish which site, N(py) or 
N(pyz), has a higher charge and thus can be ranked as the best hydrogen bond acceptor. Solvent 
assisted grinding using twenty-one carboxylic acids was combined with 2, 3, and 4; results from 
the IR data which gave a positive result (based on O-H···N stretches from the IR spectra) were 
then converted to solution experiments to generate single crystals. Single crystal data allow us to 
make inferences on binding preferences, if the two sites are significantly different in terms of 
their ability to act as a hydrogen-bond acceptor. A flowchart for the methodology is shown in 
Figure 3.5. 
 
Figure 3-5 Flowchart for determining a correlation between charge and observed 
structural motifs. 
 
This chapter will address the following questions: 
I. Can charge calculations be used to predict binding preferences? Hypothesis: 
AM1 calculations can be used to give relative strengths of N(py) and 
N(pyz)hydrogen bond acceptor sites, and the carboxylic acid donor will prefer the 
site with the highest charge. 
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II. Can co-crystal or salt formation be determined from changes in the IR spectrum? 
Hypothesis: Changes in the carbonyl C=O stretch and the presence of broad O-
H···N stretches in the 2500 cm
-1
 and 1900 cm
-1
 regions indicate a reaction; if the 
shifts in the C=O are small, co-crystal formation is the likely outcome. If the C=O 
disappears and two carboxylate COO
-
 stretches appear, salt formation is the likely 
outcome. 
III. Can we determine binding preferences of carboxylic acids for N(py) or N(pyz) 
from the single crystal data? Hypothesis: Carboxylic acids, when given the 
choice between N(py) or N(pyz), will choose the site with the highest charge and 
lowest pKb value, N(py). However, two possible synthons that can occur are 
synthon 1 and synthon 2, respectively, Figures 3.6 and 3.7. 
 
 
Figure 3-6  The carboxylic acid···pyridine heterosynthon (Synthon 1). 
 
 
Figure 3-7  The carboxylic acid···pyrazole heterosynthon (Synthon 2). 
 
Despite pyridine being a stronger base, the pyrazole nitrogen has help from a more acidic 
N-H in a two point contact. This help may tilt the balance and make the pyrazole as competitive 
as pyridine for an incoming carboxylic acid. 
 3.2 Experimental 
3.2.1 Charge calculations 
Molecular electrostatic potential (MEP) surface charge calculations were performed 
using Spartan (Wavefunction, Inc., Irvine, CA). The molecules were optimized using AM1, with 
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the maxima and minima in the electrostatic potential surface (0.002 e/au isosurface) determined 
using a positive point charge in the vacuum as a probe. 
3.2.2  Covalent synthesis 
All chemicals were purchased from Aldrich and used without further purification unless 
otherwise noted. Palladium catalyst was purchased from TCI. 
1
H and 
13
C NMR data were 
recorded on a Bruker 400 MHz instrument. Melting points were determined on a Fisher-Johns 
melting point apparatus and are uncorrected. 
3.2.2.1 Synthesis of 2-(1H-pyrazol-4-yl)pyridine, 2 
 
To a clean 250mL round bottom flask, 40mL of deionized water and 40mL of acetonitrile 
were added. Next, 4-pyrazoleboronic acid pinacol ester (1.02g, 5.3mmol) was added, followed 
by 2-iodopyridine (0.98g, 4.8mmol). Then, Na2CO3 (0.39g, 3.6mmol) and PdCl2(PPh3)2 catalyst 
(0.17g, 0.24mmol) were added. The color of the mixture turned yellow/green after the catalyst 
was added, and most of the color had disappeared after refluxing for 24 hours. The mixture was 
stirred under dinitrogen at room temperature for 30 minutes, then heated to reflux for 72 hours, 
upon which the mixture was cooled to room temperature. The crude product was extracted in 
chloroform, washed once with both water and brine (40mL each), and dried over MgSO4. The 
salt was filtered off, and the filtrate was concentrated to give a pale yellow solid. The solid was 
purified using column chromatography (silica packed with hexanes, 25% ethyl acetate as eluent, 
product appears fluorescent blue under UV light). White crystalline solid (0.386g, 55.6%). Mp: 
130-133°C. 
1
H NMR (400 MHz, CDCl3)  ppm: 11.27 (br. s., 1 H), 8.59 (d, J=0.78 Hz, 1 H), 
8.14 (br. s., 2 H), 7.69 (d, J=1.56 Hz, 1 H), 7.52 (d, J=5.86 Hz, 1 H), 7.14 (br. s., 1 H), Figure A-
7. 
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3.2.2.2 Synthesis of 3-(1H-pyrazol-4-yl)pyridine, 3 
 
 
To a clean 250mL round bottom flask, 40mL of deionized water and 40mL of acetonitrile 
were added. Next, 4-pyrazoleboronic acid pinacol ester (1.90g, 9.77mmol) was added, followed 
by 3-iodopyridine (1.82g, 8.88mmol). Then, Na2CO3 (0.71g, 6.66mmol) and PdCl2(PPh3)2 
catalyst (0.312g, 0.444mmol) were added. The color of the mixture turned yellow/green after the 
catalyst was added, and most of the color had disappeared after refluxing for 24 hours. The 
mixture was stirred under dinitrogen at room temperature for 30 minutes, then heated to reflux 
for 72 hours, upon which the mixture was cooled to room temperature. The crude product was 
extracted in chloroform, washed once with both water and brine (40mL each), and dried over 
MgSO4. The salt was filtered off, and the filtrate was concentrated to give a brown oil. The oil 
was purified using column chromatography (silica packed with hexanes, 55% ethyl acetate as 
eluent, product appears fluorescent blue under UV light). Off-white crystalline solid (0.55g, 
42.6%). Mp: 115-117°C. 
1
H NMR (400 MHz, CDCl3)  ppm: 8.82 (s, 1 H), 8.51 (d, J=5.08 Hz, 
1 H), 7.93 (s, 2 H), 7.81 (d, J=7.81 Hz, 1 H), 7.29 - 7.39 (m, 1 H), Figure A-8. 
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3.2.2.3 Synthesis of 4-(1H-pyrazol-4-yl)pyridine, 4  
 
 
To a clean 250mL round bottom flask, 40mL of deionized water and 40mL of acetonitrile 
were added. Next, 4-pyrazoleboronic acid pinacol ester (0.90g, 4.62mmol) was added, followed 
by 4-iodopyridine (0.861g, 4.20mmol). Then, Na2CO3 (0.334g, 3.15mmol) and PdCl2(PPh3)2 
catalyst (0.147g, 0.210mmol) were added. The color of the mixture turned yellow/green after the 
catalyst was added, and most of the color had disappeared after refluxing for 24 hours. The 
mixture was stirred under dinitrogen at room temperature for 30 minutes, then heated to reflux 
for 72 hours, upon which the mixture was cooled to room temperature. The crude product was 
extracted in chloroform, washed once with both water and brine (40mL each), and dried over 
MgSO4. The salt was filtered off, and the filtrate was concentrated to give a tan colored solid. 
The solid was purified using column chromatography (silica packed with hexanes, 55% ethyl 
acetate as eluent, product appears fluorescent blue under UV light). Yellow crystalline solid 
(0.114g, 18.7%). Mp: 194-197°C. 
1
H NMR (400 MHz, CDCl3)  ppm: 10.47 (br. s, 1 H), 8.60 
(d, J=5.86 Hz, 2 H), 7.99 (s, 2 H), 7.42 (d, J=5.86 Hz, 2 H), Figure A-9. 
3.2.2.4 Synthesis of 2-(1H-pyrazol-4-yl)pyridine:4-cyanobenzoic acid (1:1), 2:H 
To a vial, 2-(1H-pyrazol-4-yl)pyridine (2.4mg, 0.017mmol) was added with 4-
cyanobenzoic acid (2.4mg, 0.016mmol). The solids were dissolved in methanol (0.5mL) and left 
for slow evaporation (loose screw cap). Colorless prisms were obtained after a few days. Mp: 
169-171°C.  
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3.2.2.5 Synthesis of 2-(1H-pyrazol-4-yl)pyridine:4-nitrobenzoic acid (1:1), 2:K 
To a vial, 2-(1H-pyrazol-4-yl)pyridine (2.8mg, 0.019mmol) was added with 4-
nitrobenzoic acid (3.3mg, 0.020mmol). The solids were dissolved in methanol (1 mL), heated 
gently, and left for slow evaporation (loose screw cap). Colorless prisms were obtained after a 
few days. Mp: 216-217°C. 
3.2.2.6 Synthesis of 3-(1H-pyrazol-4-yl)pyridine:2,4-difluorobenzoic acid (1:2), 3:M2 
To a vial, 3-(1H-pyrazol-4-yl)pyridine (1.0M solution in ethanol, 335μL) was added. In a 
separate vial, 2,4-difluorobenzoic acid (5.3mg, 0.034mmol) was dissolved in ethanol (0.5mL). 
The two solutions were combined and left for slow evaporation (parafilm, 1 pinhole). Colorless 
plates were obtained after a few days. Mp: 105-107°C.  
3.2.2.7 Synthesis of 4-(1H-pyrazol-4-yl)pyridine:4-nitrobenzoic acid (1:2), 4:K2 
To a vial, 4-(1H-pyrazol-4-yl)pyridine (3.7mg, 0.026mmol) was added with 4-
nitrobenzoic acid (4.3mg, 0.026mmol). The solids were dissolved in ethanol (0.8mL), heated, 
then filtered while still hot. The filtrate was left to stand and slowly evaporate (parafilm, 1 
pinhole). Gold prisms were obtained after a few days. Mp: 190-192°C. 
3.2.2.8 Synthesis of 2-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate (1:1), 2:U 
To a vial, 2-(1H-pyrazol-4-yl)pyridine (14.0mg, 0.0964mmol) was added with 2,4-
dinitrobenzoic acid (20.0mg, 0.0964mmol). The solids were dissolved in methanol (1.5mL), 
heated, and left for slow evaporation (loose screw cap). Colorless prisms were obtained after a 
few days. Mp: 216-218°C. 
3.2.2.9 Synthesis of 3-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate (1:1), 3:U 
To a vial, 3-(1H-pyrazol-4-yl)pyridine (10mg, 0.069mmol) was added and dissolved in 
0.5mL of methanol. To the same vial, 2,4-dinitrobenzoic acid (15.0mg, 0.071mmol) was added. 
The solution was heated and left for slow evaporation (parafilm, 1 pinhole). Colorless plates 
were obtained after a few days. Mp: 196-197°C.  
3.2.2.10 Synthesis of 4-(1H-pyrazol-4-yl)pyridinium:4-cyanobenzoate (1:1), 4:H 
To a vial, 4-(1H-pyrazol-4-yl)pyridine (10.4mg, 0.0714mmol) was added with 4-
cyanobenzoic acid (10.5mg, 0.0714mmol). The solids were dissolved in methanol (1.0mL), 
48 
 
heated, then left to stand and slowly evaporate (loose screw cap). Colorless plates were obtained 
after a few days. Mp: 185-187°C. 
3.2.2.11 Synthesis of 4-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate dihydrate (1:1:2), 
4:U:(H2O)2 
To a vial, 4-(1H-pyrazol-4-yl)pyridine (2.6mg, 0.018mmol) was added with 2,4-
dinitrobenzoic acid (3.8mg, 0.018mmol). The solids were dissolved in methanol (0.5mL) and left 
for slow evaporation (loose screw cap). Colorless prisms were obtained after a few days. Mp: 
197-199°C.  
3.2.3 IR spectroscopy 
Infrared spectra were collected on a Thermo Scientific Nicolet 380 FT-IR using a ZnSe 
crystal. The solids obtained from grinding (or solution) experiments were analyzed by placing 
the solid directly on the crystal and performing 32 scans. 
 
 3.3 Results 
3.3.1 MEP surface calculations 
In order to get an idea of the relative strengths of the hydrogen-bond acceptor sites from 
the ditopic molecules, molecular electrostatic potential (MEP) surface calculations were 
performed. The two values are used to rank the relative strengths of the pyridine N(py) and 
pyrazole N(pyz) sites. The MEP surface energies are shown in Table 3.1 and Figure 3.8. 
 
Table 3.1 AM1 Molecular electrostatic surface potential energies for ditopics 2, 3, and 4. 
Ditopic molecule E(Npy) kJ mol
-1
 E(Npyz) kJ mol
-1
 E(N-H) kJ mol
-1
 
2 -270 -234 +187 
3 -281 -228 +200 
4 -276 -226 +205 
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Figure 3-8 MEP surfaces of the ditopic molecules indicating the distribution of charge. 
Red surfaces indicate hydrogen-bond acceptor sites; blue indicates hydrogen bond donor sites. 
3.3.2 Covalent synthesis 
Three ditopic molecules were synthesized using a Suzuki-Miyaura cross-coupling 
reaction and the products were purified using column chromatography. Previous coupling 
reactions to pyrazole involved multistep synthesis via an aldehyde intermediate8 (route 1); 
coupling a 4-halo pyrazole to pyridine boronic acid did not give the desired product (route 2); 
however, reversing the substituents by placing the boronic acid substituent on the pyrazole and 
the halogen on the pyridine gave the direct C-C coupled product in moderate to good yields and 
reduced the number of steps to one (route 3), Figure 3.9.  
 
Figure 3-9 Synthetic routes to obtaining the target molecules 2, 3, and 4.  
  
3.3.3 Infrared data 
The ditopic molecules were screened with twenty-one carboxylic acids of varying pKa 
values and charge using solvent-assisted grinding, Table 3.2.  
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Table 3.2 Aromatic carboxylic acids used in the study.  
Label (pKa)
9 Acid  
A (4.57 +/- 0.10) 4-Hydroxybenzoic acid 
B (4.45 +/- 0.10) 4-Hydroxy-3-methoxy benzoic acid 
C (4.34 +/- 0.10) 3,5-Dimethylbenzoic acid 
D (4.08 +/- 0.10) 3-Hydroxybenzoic acid 
E (4.02 +/- 0.10) 4-Iodobenzoic acid 
F (3.97 +/- 0.10) 4-Chlorobenzoic acid 
G (3.64 +/- 0.10) 3-Cyanobenzoic acid 
H (3.54 +/- 0.10) 4-Cyanobenzoic acid 
I (3.48 +/- 0.10) 3-Nitrobenzoic acid 
J (3.46 +/- 0.10) 3-Bromo-5-iodobenzoic acid 
K (3.42 +/- 0.10) 4-Nitrobenzoic acid 
L (3.27 +/- 0.10) 2-Fluorobenzoic acid 
M (3.21 +/- 0.10) 2,4-Difluorobenzoic acid 
N (2.97 +/- 0.25) 2-Chlorobenzoic acid 
O (2.77 +/- 0.10) 3,5-Dinitrobenzoic acid 
P (2.34 +/- 0.10) 2,6-Difluorobenzoic acid 
Q (2.19 +/- 0.25) 2-Nitrobenzoic acid 
R (1.93 +/- 0.10) 2-Fluoro-6-iodobenzoic acid 
S (1.69 +/- 0.10) 2,6-Dichlorobenzoic acid 
T (1.60 +/- 0.10) Pentafluorobenzoic acid 
U (1.43 +/- 0.25) 2,4-Dinitrobenzoic acid 
 
3.3.4 Determining co-crystal formation by infra-red (IR) spectroscopy 
Using infra-red spectroscopy, it is possible to determine the interaction between a 
carboxylic acid and an N-heterocycle by the presence of broad stretches in the 2500 cm
-1
 and 
1900 cm
-1
 region.10 The broad stretches in this region correspond to O-H···N stretches, and are 
only present if the two molecules are forming an intermolecular interaction. Furthermore, shifts 
in the carbonyl (C=O) stretch (normalized against the neutral acid) or the disappearance of the 
C=O stretch and appearance of two carboxylate COO
-
 stretches indicate co-crystal or salt 
formation, respectively. An example of an IR spectrum which shows a reaction between acid and 
base resulting in a co-crystal is shown in Figure 3.10. 
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Figure 3-10 IR spectrum of reaction between 4 and K. Evidence of O-H···N interactions 
are circled. Change in the carbonyl C=O stretch is 4 cm
-1
. 
 
The results from the screening experiments between twenty-one carboxylic acids and 
ditopics 2, 3, and 4 are summarized in Table 3.3, with prominent IR stretches noted. The 
corresponding supramolecular yield (calculated as the number of positive hits) is given in the last 
row. 
Table 3.3 Summary of prominent IR stretches (cm
-1
) from the grinding experiments 
between three ditopic molecules and twenty-one carboxylic acids.  
 2 3 4 
4-Hydroxybenzoic acid 2487, 1917, 1678 2452, 1928, 1666 2460, 1924, 1659 
4-Hydroxy-3-methoxy benzoic 
acid No rxn 2565, 1866, 1670 2472, 1952, 1666 
3,5-Dimethylbenzoic acid No rxn 2499, 1913, 1686 2409, 1921, 1670 
3-Hydroxybenzoic acid 2581, 1846, 1670 2577, 1846, 1670 2569, 1889, 1651 
4-Iodobenzoic acid 2483, 1870, 1682 2546, 1862, 1670 2526, 1862, 1678 
4-Chlorobenzoic acid 2479, 1878, 1682 2425, 1921, 1686 2444, 1893, 1686 
3-Cyanobenzoic acid 2476, 1866, 1678 2503, 1909, 1670 2460, 1921, 1690 
4-Cyanobenzoic acid 2413, 1862, 1698 2433, 1921, 1658, 1424 2460, 2093, 1944, 1665, 1402 
3-Nitrobenzoic acid 2413, 1878, 1709 2464, 1905, 1706 2456, 1850, 1690 
3-Bromo-5-iodobenzoic acid 2479, 1858, 1706 2476, 1901, 1702 2433, 1858, 1682 
4-Nitrobenzoic acid 2436, 1854, 1698 2421, 1932, 1682 2444, 1870, 1690 
2-Fluorobenzoic acid 2468, 1885, 1682 2479, 1921, 1698 2620, 2104, 1631, 1377 
2,4-Difluorobenzoic acid 2663, 1878, 1690 2452, 1874, 1666 2464, 1960, 1674 
2-Chlorobenzoic acid 2479, 1932, 1702 2472, 1917, 1702 2487, 1909, 1627, 1343 
3,5-Dinitrobenzoic acid 2448, 2003, 1620, 1430 2835, 1913, 1623, 1425 2538, 2139, 2038, 1631, 1403 
2,6-Difluorobenzoic acid 2479, 1940, 1621, 1382 2460, 2167, 1878, 1616, 1378 2456, 1956, 1631, 1385 
2-Nitrobenzoic acid 2495, 1928, 1597, 1434 2452, 1901, 1721 2464, 2003, 1698 
2-Fluoro-6-iodobenzoic acid 2444, 1901,1622, 1390 2550, 2116, 1592, 1376 2648, 1995, 1634, 1388 
52 
 
2,6-Dichlorobenzoic acid 2433, 1944, 1641, 1441 2476, 2120, 1952, 1698 2479, 1932, 1631, 1427 
Pentafluorobenzoic acid 2491, 2089, 1639, 1403 2433, 2155, 1647, 1623, 1407 2522, 1932, 1604, 1394 
2,4-Dinitrobenzoic acid 2472, 2061, 1584, 1373 2464, 2175, 2010, 1620, 1397 2515, 2112, 1631, 1397 
Success rate 19/21 = 90% 21/21 = 100% 21/21 = 100% 
 
Co-crystals: 
3.3.5 Crystal structure of 2-(1H-pyrazol-4-yl)pyridine:4-cyanobenzoic acid (1:1), 2:H 
The crystal structure of 2:H shows a 1:1 ratio between acid and ditopic molecule and 
hydrogen bonding occurs between a carboxylic acid and a pyrazole nitrogen atom, giving an O-
H···N(pyz) distance of 2.6015(11)Å and an angle of 174(15)°. The acidic proton remains on the 
carboxylic acid, as evidenced by the C-O/C=O ratio of 1.08. Ditopic molecules are connected 
into a catemer which forms between the pyrazole N-H proton and a pyridine nitrogen atom, a N-
H···N(py) distance of 2.8555(13)Å and an angle of 167(13)°. The N-H proton remains on the 
pyrazole, as evidenced by a C-N(py)-C angle of 118(9)°, Figure 3.11.   
 
 
Figure 3-11 Catemer in the crystal structure of 2:H. 
3.3.6 Crystal structure of 2-(1H-pyrazol-4-yl)pyridine:4-nitrobenzoic acid (1:1), 2:K 
The crystal structure of 2:K shows a 1:1 ratio between acid and ditopic molecule where 
hydrogen bonding occurs between the carboxylic acid and pyrazole nitrogen atom, giving an O-
H···N(pyz) distance of 2.588(2)Å and an angle of 167(2)°. The acidic proton remains on the 
carboxylic acid, as evidenced by the C-O/C=O ratio of 1.09. The ditopic molecules are 
connected into a catemer through the pyrazole N-H proton and a pyridine nitrogen atom, with a 
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N-H···N(py) distance of 2.872(3)Å and an angle of 170(2)°. The N-H proton remains on the 
pyrazole, as evidenced by a C-N(py)-C angle of 118(18)°, Figure 3.12.   
 
 
Figure 3-12 Catemer in the crystal structure of 2:K. 
3.3.7 Crystal structure of 3-(1H-pyrazol-4-yl)pyridine:bis-2,4-difluorobenzoic acid (1:2), 3:M2 
The crystal structure of 3:M2 shows a 1:2 ratio between the ditopic molecule and the acid. 
Two predominant interactions are observed. At the pyridine site, a two-point contact exists 
between carboxylic acid and pyridine nitrogen atom, giving an O-H···N(py) distance of 
2.662(6)Å and an angle of 152(7)°; the C-H···O=C distance is 2.568Å. The acidic proton 
remains on the carboxylic acid, and the C-O/C=O ratio is 1.09 and the C-N(py)-C angle is 
118(5)°. On the pyrazole end, a second carboxylic acid bridges two symmetry-related ditopics 
through the carboxylic acid hydrogen atom and pyrazole nitrogen atom, as well as through the 
pyrazole N-H proton and carboxylic acid carbonyl interaction, respectively: O-H···N(pyz) 
distance is 2.693(6)Å and the angle is 139(9)°. The N-H···O=C distance is 2.806(6) and the 
angle is 141(7)°. The proton remains on the carboxylic acid, as evidenced by the C-O/C=O ratio 
of 1.06, Figure 3.13.  
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Figure 3-13 Two predominant interactions in the crystal structure of 3:M2. 
3.3.8 Crystal structure of 4-(1H-pyrazol-4-yl)pyridine:bis-4-nitrobenzoic acid (1:2), 4:K2  
The crystal structure of 4:K2 shows a 1:2 ratio between heterocycle and acid. Two predominant 
interactions are observed. On the pyridine end, a two-point contact exists between a carboxylic 
acid and a pyridine nitrogen atom, where the O-H···N(py) distance is 2.545(3)Å and the angle is 
178(3)°; the C-H···O=C distance is 2.521Å. The acidic proton remains on the carboxylic acid, 
where the C-O/C=O ratio is 1.06 and the C-N(py)-C angle is 119(2)°. On the pyrazole end, a 
second acid forms a hetero synthon with a pyrazole nitrogen atom, and the pyrazole N-H proton 
interacts with the carbonyl oxygen atom from the carboxylic acid: O-H···N(pyz) distance is 
2.672(3)Å and the angle is 175(3)°; N-H···O=C distance is 2.820(3) and the angle is 146(3)°. 
The ratio of C-O/C=O is 1.07, Figure 3.14.  
 
Figure 3-14 Supermolecule formed in the crystal structure of 4:K2. 
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Salts: 
3.3.9 Crystal structure of 2-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate (1:1), 2:U 
In the crystal structure of 2:U proton transfer occurs between the carboxylic acid and 
pyridine nitrogen atom, giving a charge-assisted N
+
-H···
-
O distance of 2.663(3)Å with a C-N(py)-
C angle of 123(2)°. The C-O
-
/C-O
-
 carboxylate bond ratio is 1.01, indicating the proton has been 
transferred. A second charge-assisted N-H···
-
O interaction occurs between the pyrazole N-H 
proton and carboxylate, 2.830(3)Å and 170(3)°, Figure 3.15.  
 
Figure 3-15 Zig-zag chain formed in 2:U. 
3.3.10 Crystal structure of 3-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate (1:1), 3:U  
In the crystal structure of 3:U proton transfer occurs between the carboxylic acid and 
pyridine nitrogen atom, giving a charge-assisted N
+
-H···
-
O distance of 2.6436(16)Å and an angle 
of 179(16)°; the C-N(py)-C angle is 120(11)° and C-O
-
/C-O
-
 carboxylate bond ratio is 1.04, 
indicating the proton has been transferred. A second charge-assisted N-H···
-
O interaction occurs 
between the pyrazole N-H proton and carboxylate, 2.7738(16)Å and 165(17)°, Figure 3.16.   
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Figure 3-16 Proton transfer from acid to base in the crystal structure of 3:U. 
3.3.11 Crystal structure of 4-(1H-pyrazol-4-yl)pyridinium:4-cyanobenzoate (1:1), 4:H 
The crystal structure of 4:H shows a zig-zag chain formed through proton transfer from 
the carboxylic acid to the pyridine nitrogen atom. A carboxylate bridges two ditopic molecules, 
where charge-assisted N
+
-H···
-
O distance is 2.5910(11) Å with an angle of 176(13)°. The C-
N(py)-C bond angle is 121(8)°. The pyrazole N-H proton interacts with a carboxylate, giving an 
N-H···
-
O distance of 2.7777(11) Å and an angle of 166(12)°. The C-O
-
/C-O
-
 carboxylate bond 
ratio is 1.04, indicating the proton has been transferred, Figure 3.17.  
 
Figure 3-17 Part of the zig-zag chain formed through proton transfer from acid to base in 
the crystal structure of 4:H. 
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3.3.12 Crystal structure of 4-(1H-pyrazol-4-yl)pyridinium:2,4-dinitrobenzoate dihydrate 
(1:1:2), 4:U:(H2O)2 
The crystal structure of 4:U:(H2O)2 shows a hydrated salt. Proton transfer occurs from 
the carboxylic acid to a pyridine nitrogen atom, giving a charge-assisted N
+
-H···
-
O distance of 
2.5910(11) Å, 176(13)°. The C-N(py)-C bond angle is 121(8)°. The carboxylate also interacts with 
water, where the Ow-H···
-
O distance is 2.7777(11) Å with an angle of 166(12)°. The C-O
-
/C-O
-
 
carboxylate bond ratio is 1.04, indicating the proton has been transferred. The pyrazole N-H 
proton interacts with water through N-H···Ow hydrogen bonds, in addition to Ow-H···N 
hydrogen bonds with the pyrazole nitrogen atom, Figure 3.18. 
 
Figure 3-18 Hydrated salt formed in the reaction between 4 and U. 
 3.4 Discussion 
3.4.1 What do the AM1 charge calculations tell us about where binding should take place?  
In all cases, the pyridine nitrogen atom, N(py), carries the largest negative charge, with 
an average AM1 value of -276 kJ/mol (Table 3.1). The pyrazole nitrogen atom, N(pyz), carries a 
lower negative charge, with an average AM1 value of -229 kJ/mol (Table 3.1). Therefore, we 
would expect the pyridine nitrogen atom to be the most attractive site for an incoming carboxylic 
acid or N-H proton, and the best hydrogen bond acceptor; the pyrazole nitrogen atom would be 
ranked as the second best acceptor site. 
The charge on the pyrazole N-H proton carries the largest positive charge, with an 
average AM1 value of +197 kJ/mol (Table 3.1). Therefore, the N-H proton would be ranked as 
the best hydrogen bond donor and we would predict the N-H proton to interact with the best 
acceptor site, N(py). On the other hand, all of the carboxylic acids used carry a lower positive 
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charge than the pyrazole N-H proton, with values ranging from +130-190 kJ/mol. All acids 
would be ranked as the second best hydrogen bond donor. 
3.4.2 Can we determine co-crystal or salt formation from the IR data? 
The IR data show a 90-100% success rate for reactions between twenty-one carboxylic 
acids and ditopics 2, 3, and 4; this is an increase in the success rate from the system in Chapter 2, 
which contained only pyrazole (and substituted pyrazole). The results show that the addition of a 
pyridine moiety increases the success rate for a reaction (denoted as rxn), suggesting that 
pyridine is slightly more active than the pyrazole when combined with carboxylic acids. 
Furthermore, the IR data support our original hypothesis; the addition of a stronger hydrogen 
bond acceptor site to the pyrazole backbone should increase the supramolecular yield. From 
Chapter 2, the success rate for a reaction between pyrazole and carboxylic acid was between 55-
70%; addition of the pyridine moiety increases the success rate to 90-100%.   
To determine unambiguously whether a co-crystal or salt forms requires both IR and 
single crystal data; therefore, the results presented in Table 3.4 represent a prediction based on 
changes in the C=O band from the reaction compared to the neutral acid. For co-crystal 
formation, the C=O band is expected to change slightly. When the acidic proton is transferred 
from the acid to the base, a carboxylate anion, COO
-
, is expected to form. The C=O band would 
thus disappear and an asymmetric COO
-
 band combined with a weaker symmetric COO
-
 band is 
expected to appear.11 
Table 3.4 Summary of changes in the carbonyl (C=O) after reaction (rxn).  
Acid (C=O) 2 3 4 
(C=O) (COO-) Pred. (C=O) (COO-) Pred. (C=O) (COO-) Pred. 
4-Hydroxybenzoic acid 
(1668) 1678 - co-crystal 1666 - co-crystal 1659 - co-crystal 
4-Hydroxy-3-methoxy 
benzoic acid (1671) No rxn - - 1670 - co-crystal 1666 - co-crystal 
3,5-Dimethylbenzoic acid 
(1679) No rxn - - 1686 - co-crystal 1670 - co-crystal 
3-Hydroxybenzoic acid 
(1678) 1670 - co-crystal 1670 - co-crystal 1651 27 salt 
4-Iodobenzoic acid 
(1667) 1682 - co-crystal 1670 - co-crystal 1678 - co-crystal 
4-Chlorobenzoic acid 
(1678) 1682 - co-crystal 1686 - co-crystal 1686 - co-crystal 
3-Cyanobenzoic acid 
(1683) 1678 - co-crystal 1670 - co-crystal 1690 - co-crystal 
4-Cyanobenzoic acid 
(1691) 1698 - co-crystal - 
1658, 
1424 
salt - 
1665, 
1402 
salt 
3-Nitrobenzoic acid 
(1686) 1709  co-crystal 1706 - co-crystal 1690 - co-crystal 
59 
 
3-Bromo-5-iodobenzoic 
acid (1699) 1706 - co-crystal 1702 - co-crystal 1682 - co-crystal 
4-Nitrobenzoic acid 
(1686) 1698 - co-crystal 1682 - co-crystal 1690 - co-crystal 
2-Fluorobenzoic acid 
(1687) 1682 - co-crystal 1698 - co-crystal - 
1631, 
1377 
salt 
2,4-Difluorobenzoic acid 
(1682) 1690 - co-crystal 1666 - co-crystal 1674 - co-crystal 
2-Chlorobenzoic acid 
(1679) 1702  co-crystal 1702 - co-crystal - 
1672, 
1343 
salt 
3,5-Dinitrobenzoic acid 
(1698) - 
1620, 
1430 
salt - 
1623, 
1425 
salt - 
1631, 
1403 
salt 
2,6-Difluorobenzoic acid 
(1686) - 
1621, 
1382 
salt - 
1616, 
1378 
salt - 
1631, 
1385 
salt 
2-Nitrobenzoic acid 
(1671) - 
1597, 
1434 
salt 1721 - co-crystal 1698 -  co-crystal 
2-Fluoro-6-iodobenzoic 
acid (1699) - 
1622, 
1390 
salt - 
1592, 
1376 
salt - 
1634, 
1388 
salt 
2,6-Dichlorobenzoic acid 
(1704) - 
1641, 
1441 
salt 1698 6 co-crystal - 
1631, 
1427 
salt 
Pentafluorobenzoic acid 
(1709) - 
1639, 
1403 
salt - 
1623, 
1407 
salt - 
1604, 
1394 
salt 
2,4-Dinitrobenzoic acid 
(1716) - 
1584, 
1373 
salt - 
1620, 
1397 
salt - 
1631, 
1397 
salt 
 
From the data in Table 3.4, changes in the C=O which were small were predicted to give 
a co-crystal. In a few cases, the C=O stretch shifted over 20 wavenumbers, yet the prediction was 
co-crystal formation based on the overall appearance of the spectrum. When the C=O 
disappeared, an asymmetric carboxylate (COO
-
) band appeared around 1650-1590 cm
-1
, 
combined with a weaker symmetric carboxylate stretch in the 1400 cm
-1
 region. New bands that 
appeared were assigned as salt formation. 
In a similar study involving 2-aminopyrimidines, Aakeröy et al.12 were able to correlate 
the difference between co-crystal and salt formation by looking at various changes in the IR 
spectra. The results showed that co-crystals displayed stretching frequencies around 1700 cm
-1
 
(consistent with neutral acid C=O) and salts displayed specific stretches near 1650 cm
-1
.  
The results in Table 3.4 also indicate that co-crystal formation is the likely outcome when 
using acids with pKa values lower than 2-chlorobenzoic acid (pKa < 2.97). In our system, which 
is expected to contain either carboxylic acid···pyridine or carboxylic acid···pyrazole 
interactions, assignments of either co-crystal or salt display a clear cutoff. If we consider the pKa 
of the conjugate acid of pyridine (5.25), then the results from Table 3.4 support the ‘rule of 3’13 
which suggests that a ΔpKa value between 0 to 3.75 is likely to favor a co-crystal. If the ΔpKa is 
greater than 3.75, proton transfer is the likely outcome. As a comparison, the ΔpKa values were 
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calculated for the ditopics (using the pKa of pyridine as the value for the ditopic). A summary of 
the results is shown in Table 3.5.  
Table 3.5 Summary of ΔpKa and the corresponding structures obtained from the single 
crystal data. The number of structures is given in parentheses; dash marks indicate no structures. 
pKa of pyridine pKa of carboxylic acid Δ pKa Structures 
5.25 4.57 0.68 - 
5.25 4.45 0.8 - 
5.25 4.34 0.91 - 
5.25 4.08 1.17 - 
5.25 4.02 1.23 - 
5.25 3.97 1.28 - 
5.25 3.64 1.61 - 
5.25 3.54 1.71 Co-crystal (1), Salt (1) 
5.25 3.48 1.77 - 
5.25 3.46 1.79 - 
5.25 3.42 1.83 Co-crystal (2) 
5.25 3.27 1.98 - 
5.25 3.21 2.04 Co-crystal (1) 
5.25 2.97 2.28 - 
5.25 2.77 2.48 - 
5.25 2.34 2.91 - 
5.25 2.19 3.06 - 
5.25 1.93 3.32 - 
5.25 1.69 3.56 - 
5.25 1.6 3.65 - 
5.25 1.43 3.82 Salt (3) 
 
Although the pKa of the pyridine site on the ditopic ligand may vary compared to the pKa 
value of pyridine by itself (5.25), the value certainly allows us to verify the ‘rule of 3’ and shows 
how well it fits with our results. Not surprisingly, the rule of three predicted salt formation for all 
combinations with 2,4-dinitrobenzoic acid, which corroborates the single crystal results obtained. 
Moreover, co-crystal predictions also fit with the rule of three. On the other hand, there was one 
salt structure which did not fit with the prediction.  
The importance of forming salts or co-crystals has a large impact on the outcome of 
pharmaceutical formulations, and liquid forms of pharmaceutical co-crystals at the boundary of 
salt formation has recently been explored by Rogers et al.14 in addition to a recent paper by 
MacGillivray et al.15 who looked at supramolecular complexes of sulfadiazine and pyridine at the 
co-crystal-salt boundary. 
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3.4.3 Can we group the interactions in the co-crystals and salts obtained from the single 
crystal data? 
Single crystal data confirmed the presence of both carboxylic acid···pyridine and 
carboxylic acid···pyrazole interactions in the structures, suggesting that there is not a significant 
difference between the two acceptor sites. Two groups of interactions were found in the co-
crystals as well as the salts, and are described in the following sections.  
3.4.3.1 Co-crystals 
There are two groups of interactions observed in the four co-crystals. In the first group 
the carboxylic acid binds to both pyridine and pyrazole nitrogen atoms; the N-H proton is 
involved in a hetero synthon via N-H···O=C(carbonyl) hydrogen bonds. In the second group the 
carboxylic acid interacts exclusively with the pyrazole nitrogen atom, forming O-H···N(pyz) 
hydrogen bonds. The N-H proton forms a N-H···N(py) hydrogen bond to the pyridine nitrogen 
atom. A summary of the interactions is shown in Figure 3.19. 
 
Figure 3-19 Interactions observed in the four co-crystals. 
 
3.4.3.2 Salts 
In the four salt structures, proton transfer occurred to the pyridine nitrogen atom. This 
result is not surprising, considering the pKb value of pyridine is lower than that of pyrazole (i.e. 
stronger base) and also indicates the pyridinium ion is more stable than pyrazolium ion. Proton 
transfer reactions all involved pyridinium···carboxylate charge-assisted synthons. There was one 
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structure which incorporated water into the crystal lattice, which is not surprising considering 
carboxylates (COO
-
) are very good hydrogen-bond acceptors.3 This result is consistent with the 
observations made from Chapter 2, where neutral acids, neutral pyrazole molecules, or water 
molecules frequently appear in the lattice when proton transfer events take place. A summary of 
the interactions observed in the co-crystals and salts is shown in Table 3.6. 
 
Table 3.6 Groups of primary interactions between the co-crystals and salts.  
Group number Primary interactions Co-crystal hits Salt hits 
1 O-H···N(pyz), N-H···N(py) 2 - 
2 
O-H···N(py), O-H···N(pyz) 
N-H···O=C 
2 - 
3 N-H
+
···
-
O-C, N-H···
-
O-C - 3 
4 
N-H
+
···
-
O-C, N-H···Ow, 
Ow-H···O, Ow-H···N 
- 1 
 
In summary, 
I. Charge calculations can be used to successfully rank the relative strengths of 
hydrogen-bond donor and acceptor sites.  
II. Co-crystals displayed small changes in the IR spectrum, whereas salt formation 
resulted in the disappearance of the C=O and appearance of two carboxylate 
COO
-
 stretches. 
III. Both carboxylic acid···pyridine and carboxylic acid···pyrazole interactions were 
observed, suggesting that there is not a significant difference and carboxylic 
acid···pyrazole synthons can compete with carboxylic acid···pyridine synthons. 
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Are triazoles competitive with pyridine for hydrogen bonds? Chapter 4 - 
 4.1 Introduction 
The pharmaceutical industry is a multi-billion dollar per year market. Of the many active 
pharmaceutical ingredients (API’s) that are produced, anti-fungal API’s are an important class of 
compounds. Due to such a large market, there is a constant demand for new API’s with improved 
physical properties. 
In certain cases, specific anti-fungal API’s suffer from poor physical properties, such as 
aqueous solubility and unwanted behavior during scale-up, to name a few. Poor aqueous 
solubility is a problem for administering an anti-fungal drug in the body. Anti-fungal API’s 
contain a variety of functional groups, and one group that stands out is triazole, Figure 4.1.  
 
Figure 4-1 Two groups of triazole. (I) 1H-1,2,3-triazole. (II) 1H-1,2,4-triazole.  
 
The triazole works by inhibiting the biosynthesis of sterols, an important component of 
cell walls, which results in cell death.1 Although a large number of anti-fungal active ingredients 
are used in agricultural applications, they are very important in treating fungal infections in 
humans.2 Within this class of compounds, two commonly used anti-fungal drugs are Fluconazole 
(I) and Itraconazole (II), Figure 4.2. 
 
Figure 4-2 (I) Fluconazole® and (II) Itraconazole® highlighting the triazole functional 
group. 
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Both fluconazole and itraconazole suffer from poor aqueous solubility,3
,4 which is a 
problem when administering the drug to a patient. In order to improve the physical properties of 
any API, without developing an entirely new library of target compounds, one needs to 
understand how to make alternative forms of the API without changing the structure of the 
molecule. A few examples of alternative forms of poorly soluble API that were made without 
changing the molecular structure are salts5 and co-crystals6; depending on the application, one or 
the other (or both) may help overcome some shortcomings (i.e. poor aqueous solubility) from 
existing API. 
In 2003, Remenar et al.7 synthesized a series of co-crystals Itraconazole API with various 
di-carboxylic acids in an effort to make alternative solid forms of the drug with improved 
aqueous solubility. A snapshot of the crystal structure obtained from the Itraconazole:succinc 
acid co-crystal (2:1) is shown in Figure 4.3. 
 
Figure 4-3 Itraconazole:succinic acid co-crystal (2:1).
7
 
 
In the crystal structure, the succinic acid molecule acts as a ‘tether’ which bridges two 
drug molecules through O-H···N4(trz) hydrogen bonds. No interaction was observed between 
N2(trz) nitrogen, indicating that the N4(trz) acts as a better hydrogen-bond acceptor site; this 
observation is not surprising, considering N4(trz) carries a higher electrostatic charge and is also 
a better acceptor geometrically for the carboxylic acid, given its position relative to the 
carboxylic acid groups, Figure 4.4. 
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Figure 4-4 Triazole nitrogen position relative to the carboxylic acid.7 
 
Although triazole groups are often encountered on the backbone of various anti-fungal 
API’s, pyridine is often seen as well, and both groups are often found on the same molecular 
backbone. In order to successfully make new solid forms of an API a solid understanding of 
where co-formers (e.g. carboxylic acids) bind (in the case of co-crystals) or proton transfer may 
take place (in the case of salt formation) is needed.  
As a result, we decided to systematically investigate the supramolecular behavior of 
carboxylic acids with triazole/pyridine ditopic molecules by synthesizing a library of asymmetric 
ditopic molecules containing both functional groups, triazole and pyridine (IV-VII), Figure 4.5.  
 
Figure 4-5 Triazole (I-III) and triazole/pyridine asymmetric ditopic molecules (IV-VII). 
 
Since triazole contains multiple nitrogen atoms, and hence potentially more than one 
acceptor site, an incoming carboxylic acid could bind in a variety of ways. The potential 
interactions that could result from a carboxylic acid interacting with 1H-1,2,3-triazole (I, II, III) 
and 1H-1,2,4-triazole (IV, V, VI) are shown in Figure 4.6. 
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Figure 4-6 Potential interactions between carboxylic acid and triazole molecules. 
Potential interactions with 1H-1,2,3-triazole (I,II,III) and with 1H-1,2,4-triazole (IV, V, VI) are 
shown. 
 
When adding a pyridine moiety to the triazole, the number of potential binding sites 
increases further; N(py) represents the pyridine site, N2(trz), N3(trz), and N4(trz) represent 
triazole binding sites. When a carboxylic acid is introduced to the system, the acid now has a 
choice between multiple sites: a list of potential supramolecular interactions between the 
carboxylic acid and two of the asymmetric ditopic molecules is shown below (1-14), where 
interactions between acid and 4-((1H-1,2,3-triazol-1-yl)methyl)pyridine are shown in group I, 1-
7; interactions between acid and 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine are shown in group II, 
8-14, Figure 4.7.  
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Figure 4-7 Potential binding sites of two of the four triazole/pyridine asymmetric ditopic 
molecules. Group I: 4-((1H-1,2,3-triazol-1-yl)methyl)pyridine. Group II: 4-((1H-1,2,4-triazol-1-
yl)methyl)pyridine. 
 
To address the competition between N(py), N2(trz), N3(trz), and N4(trz) in the presence of 
carboxylic acids, charge calculations were performed on the molecules to establish which site, 
N(py), N2(trz), N3(trz), or N4(trz) carries the highest charge and thus would be ranked as the best 
hydrogen-bond acceptor. Solvent assisted grinding using the same library of acids from Chapter 
2 was combined with triazole and triazole/pyridine asymmetric ditopic molecules I-VII; results 
from the IR spectra which gave a reaction (based on O-H···N) broad stretches in the 2500 cm
-1
 
69 
 
and 1900 cm
-1
 region were then converted to solution experiments to generate single crystals. 
Single crystal data allow us to make inferences on binding preferences, if the four sites (N(py), 
N2(trz), N3(trz), or N4(trz)) are significantly different in terms of their ability to act as a 
hydrogen-bond acceptor. A flowchart for the approach is shown in Figure 4.8. 
 
 
Figure 4-8 Flowchart for determining a correlation between charge calculations, IR 
spectroscopy results and single crystal data. 
 
None of the proposed molecules in the library have been used for any screening study; in 
fact, there is only a handful of examples of co-crystals or salts with similar molecules.8 
Furthermore, there is no study in the literature which systematically examines the binding 
preferences of carboxylic acids for N(py), N2(trz), N3(trz), or N4(trz) when present in the same 
system (i.e. same molecular backbone).  
 
The goals of this study are as follows: 
 
I. Can charge calculations be used to predict binding preferences? Hypothesis: 
AM1 calculations will give relative electrostatic charges of N(py), N2(trz), 
70 
 
N3(trz), and N4(trz) hydrogen bond acceptor sites and allow us to rank the sites; 
the carboxylic acid donor will prefer the site which carries the highest charge.  
II. Are there specific handles which can be used to determine reaction or no reaction, 
and co-crystal or salt formation, from changes in the IR spectrum? Hypothesis: 
Changes in the carbonyl C=O stretch and the presence of broad O-H···N stretches 
in the 2500 cm
-1
 and 1900 cm
-1
 regions indicate a reaction; if the shifts in the 
C=O are small, co-crystal formation is the likely outcome. If the C=O disappears 
and two carboxylate COO
-
 stretches appear, salt formation is the likely outcome 
III. Can we determine binding preferences of carboxylic acids for N(py), N2(trz), 
N3(trz), or N4(trz) in a competitive environment from the single crystal data? 
Hypothesis: Binding preferences for carboxylic acids, when given the choice 
between N(py), N2(trz), N3(trz), or N4(trz), will choose the site which carries the 
highest charge (determined from the AM1 calculations). 
 
 4.2 Experimental 
4.2.1 Charge calculations 
Molecular electrostatic potential (MEP) surface charge calculations were performed 
using Spartan (Wavefunction, Inc., Irvine, CA). The molecules were optimized using AM1, with 
the maxima and minima in the electrostatic potential surface (0.002 e/au isosurface) determined 
using a positive point charge in the vacuum as a probe. 
4.2.2 Covalent synthesis and characterization of products 
All chemicals were purchased from Aldrich, TCI, and Combi-blocks and used without 
further purification, unless otherwise noted. 
1
H and 
13
C NMR data were recorded on a Bruker 
400 MHz instrument. Melting points were determined on a Fisher-Johns melting point apparatus 
and are uncorrected. 
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4.2.2.1 Synthesis of 3-((2H-1,2,3-triazol-2-yl)methyl)pyridine and 3-((1H-1,2,3-triazol-1-
yl)methyl)pyridine, IVa and IVb 
 
 
To a round bottom flask, 1H-1,2,3-triazole (2.13g, 30.8mmol) and acetonitrile (ACN, 
70mL) were added. To the clear solution, sodium hydroxide pellets (12.35g, 308.8mmol) were 
added and the mixture was stirred at room temperature for two hours, after which 3-
(chloromethyl)pyridine hydrochloride (5.57g, 33.96mmol) was added to the mixture and stirred 
for an additional 72 hours. The color turned milky orange and the reaction was monitored using 
TLC and 
1
H NMR. Upon completion, water (100mL) was added to dissolve any excess NaOH. 
Dichloromethane (100mL) was added and the organic layer was separated. The aqueous solution 
was washed with dichloromethane (4 x 50mL) and once with brine (50mL). The organic extracts 
were combined, dried over MgSO4, and concentrated to give a brown oil. From the oil, two 
isomers were separated using a silica column packed with hexanes (hexanes/ethyl acetate as 
eluent). The first spot yielded 0.50g of a yellow oil (15% ethyl acetate, 85% hexanes as eluent). 
The second spot yielded 1.21g of a yellow oil (43% ethyl acetate, 57% hexanes as eluent). IVa: 
1
H NMR (400 MHz, CDCl3)  ppm: 8.42 - 8.75 (m, 2H), 7.50 - 7.79 (m, 3H), 7.13 - 7.37 (m,1 
H), 5.63 (s, 2H), Figure A-10. 
13
C NMR (100 MHz, CDCl3) ppm: 149.98, 149.55, 135.88, 
135.06, 131.08, 123.79, 56.14, Figure A-11. IVb:  
1
H NMR (400 MHz, CDCl3)  ppm: 8.60 (br. 
s., 2H), 7.73 (s, 1H), 7.47 - 7.63 (m, 2H), 7.30 (d, J=3.91 Hz, 1H), 5.59 (s, 2 H), Figure A-12. 
13
C NMR (100 MHz, CDCl3)  ppm: 150.45, 149.27, 135.88, 134.75, 130.78, 124.17, 123.59, 
51.56, Figure A-13. 
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4.2.2.2 Synthesis of 4-((2H-1,2,3-triazol-2-yl)methyl)pyridine and 4-((1H-1,2,3-triazol-1-
yl)methyl)pyridine, Va and Vb  
 
 
 To a round bottom flask, 1H-1,2,3-triazole (0.812g, 11.76mmol) and freshly distilled 
tetrahydrofuran (THF, 30mL) were added. To the clear solution, sodium hydroxide pellets (4.7g, 
117.6mmol) were added and the mixture was stirred at room temperature for two hours, after 
which 4-(bromomethyl)pyridine hydrobromide (3.27g, 12.93mmol) was added and stirred for an 
additional 72 hours. THF (10mL) was used to wash the pyridine salt from the sides of the round 
bottom into the reaction mixture. The mixture turned grey/green in color upon addition and the 
reaction was monitored using TLC and 
1
H NMR. Upon completion, water (30mL) was added to 
dissolve any excess NaOH pellets. Dichloromethane (30mL) was added and the organic layer 
separated. The aqueous solution was washed with dichloromethane (4 x 50mL) and once with 
brine (50mL). The organic extracts were combined, dried over MgSO4, and concentrated to give 
a black oil. From the oil, two isomers were separated using a silica column packed with hexanes 
(hexanes/ethyl acetate as eluent). The first spot yielded 0.114g of a yellow oil (20% ethyl acetate, 
80% hexanes as eluent). The second spot yielded 0.365g of a yellow oil (35% ethyl acetate, 65% 
hexanes as eluent). Va:
 1
H NMR (400 MHz, CDCl3)  ppm: 8.58 (d, J=5.08 Hz, 2H), 7.69 (s, 
2H), 7.11 (d, J=5.47 Hz, 2H), 5.64 (s, 2H), Figure A-14. 
13
C: (100 MHz, CDCl3)  ppm: 150.37, 
144.42, 135.28, 122.49, 57.35, Figure A-15. Vb:
 1
H NMR (400 MHz, CDCl3)  ppm: 8.63 (d, 
J=6.25 Hz, 2H), 7.80 (s, 1H), 7.67 (s, 1H), 7.13 (d, J=5.47 Hz, 2H), 5.65 (s, 2H), Figure A-16. 
13
C: (100 MHz, CDCl3)  ppm: 150.67, 143.95, 134.71, 124.16, 122.22, 52.64, Figure A-17. 
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4.2.2.3 Synthesis of 3-((1H-1,2,4-triazol-1-yl)methyl)pyridine, VI 
 
 
 
To a round bottom flask, 1H-1,2,4-triazole (1.64g, 23.7mmol) and acetonitrile (ACN, 
40mL) were added. To the clear solution, sodium hydroxide pellets (9.48g, 237mmol) were 
added along with additional ACN (20mL) and the mixture was stirred at room temperature for 
two hours, after which 3-(chloromethyl)pyridine hydrochloride (4.28g, 26.1mmol) and additional 
ACN (20mL) was added to wash the sides of the round bottom and stirred for an additional 72 
hours. The color turned milky orange and the reaction was monitored using TLC and 
1
H NMR. 
Upon completion, water (100mL) was added to dissolve any excess NaOH. Dichloromethane 
(100mL) was added and the organic layer was separated. The aqueous solution was washed with 
dichloromethane (4 x 50mL) and once with brine (50mL). The organic extracts were combined, 
dried over MgSO4, and concentrated to give a brown oil. The product was isolated using a silica 
column packed with hexanes (50% ethyl acetate and 50% hexanes as eluent) to give 0.167g (4.4 
%) of a yellow oil. VI: 
1
H NMR (400 MHz, CDCl3)  ppm: 8.60 (s, 2H), 8.13 (s, 1H), 7.99 (s, 
1H), 7.60 (dd, J=8.20, 1.95 Hz, 1H), 7.28 - 7.37 (m, 1H), 5.38 (s, 2H), Figure A-18. 
13
C: (100 
MHz, CDCl3)  ppm: 152.65, 150.24, 149.31, 143.35, 135.90, 130.70, 124.06, 51.11, Figure A-
19. 
4.2.2.4 Synthesis of 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine, VII 
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To a round bottom flask, 1H-1,2,4-triazole (1.65g, 23.9mmol) and acetonitrile (ACN, 
40mL) were added. To the clear solution, sodium hydroxide pellets (9.75g, 243.8mmol) were 
added and the mixture was stirred at room temperature for three hours, after which 4-
(chloromethyl)pyridine hydrochloride (4.36g, 26.6mmol) and additional ACN (20mL) was added 
to wash the sides of the round bottom and stirred for an additional 72 hours. The color turned 
purple and the reaction was monitored using TLC and 
1
H NMR. Upon completion, water 
(100mL) was added to dissolve any excess NaOH. Dichloromethane (100mL) was added and the 
organic layer was separated. The aqueous solution was washed with dichloromethane (4 x 50mL) 
and once with brine (50mL). The organic extracts were combined, dried over MgSO4, and 
concentrated to give a black oil. The product was isolated using a silica column packed with 
hexanes (50% ethyl acetate and 50% hexanes as eluent) to give 0.211g (9.4 %) of an orange oil. 
VII: 
1
H NMR (400 MHz, CDCl3)  ppm: 8.61 (br. s., 2H), 8.17 (s, 1H), 8.01 (s, 1H), 7.10 (br. s., 
2H), 5.38 (s, 2H), Figure A-20. 
13
C: (100 MHz, CDCl3)  ppm: 152.77, 150.52, 149.90, 143.85, 
122.28, 52.22, Figure A-21. 
 
4.2.2.5 Synthesis of 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine:bis(3-nitrobenzoic) acid (1:2), 
VII:I2  
To a vial, 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine (5.1mg, 0.032mmol) was added 
followed by a solution of 3-nitrobenzoic acid (5.9mg, 0.035mmol) in methanol (1mL). The 
solution was heated and left for slow evaporation (loose screw cap). Colorless plates were 
obtained after a few days. Mp: 94-96°C. 
4.2.2.6 Synthesis of 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine:bis(4-nitrobenzoic) acid (1:2), 
VII:K2  
To a vial, 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine (5.1mg, 0.032mmol) was added 
followed by a solution of 4-nitrobenzoic acid (6.0mg, 0.036mmol) in methanol (1mL). The 
solution was heated and left for slow evaporation (loose screw cap). Colorless plates were 
obtained after a few days. Mp: 162-165°C. 
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4.2.2.7 Synthesis of 4-((1H-1,2,3-triazol-1-yl)methyl)pyridinium:3,5-dinitrobenzoate:3,5-
dinitrobenzoic acid hydrate (1:2:1), V:N2:H2O 
To a vial, 4-((1H-1,2,3-triazol-1-yl)methyl)pyridine (11.0mg, 0.0686mmol) was added 
followed by a solution of 3,5-dinitrobenzoic acid (14.6mg, 0.0686mmol) in methanol (400μL). 
The solution was heated and left for slow evaporation (loose screw cap). Colorless prisms were 
obtained after a few days. Mp: 104-107°C. 
4.2.3 IR 
Infrared spectra were collected on a Thermo Scientific Nicolet 380 FT-IR using a ZnSe 
crystal. The solids (or oily product) obtained from solvent-assisted grinding experiments were 
analyzed by placing the solid directly on the crystal and performing 32 scans. 
 4.3 Results 
4.3.1 MEP surface calculations 
Molecular electrostatic potential (MEP) surface calculations were made in order to rank 
the strengths of the hydrogen bond acceptor sites. Although a low level of theory is used (AM1)9, 
this method has proven effective for predicting binding site strengths of various hydrogen-bond 
acceptor sites. In fact, Hunter10 and co-workers11 showed that this level of theory works well for 
calculating electrostatic surface energies for small molecules. The AM1 values for the library of 
molecules used (I-VII) is shown in Table 4.1. 
Table 4.1 Molecular electrostatic surface potential (MEP) calculations for the various triazoles 
and  asymmetric ditopic triazole/pyridine molecules. Values are given in kJ/mol. 
# Structure H-N1 N(py) N2(trz) N3(trz) N4(trz) 
1 
 
+202 - -217 -277 - 
2 
 
+201 - -216 - -280 
3 
 
+271 - -165 - -238 
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4 
 
- -260 -200 -275 - 
5 
 
- -270 -200 -271 - 
6 
 
- -270 -202 - -288 
7 
 
- -268 -200 - -280 
 
4.3.2 Covalent synthesis 
Four asymmetric ditopic triazole/pyridine molecules were synthesized with different 
charges on the hydrogen bond acceptor sites, Figure 4.9. 
 
 
Figure 4-9 The four asymmetric ditopic triazole/pyridine molecules (IV-VII) used for 
screening with carboxylic acids. 
4.3.3 Infrared data 
The triazole and ditopic triazole/pyridine molecules were screened with twenty 
carboxylic acids of varying pKa strength, Table 4.2. 
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Table 4.2 Table of aromatic carboxylic acids used in the study.  
Label (pKa) Benzoic Acid  
A (4.57 +/- 0.10) 4-Hydroxybenzoic acid 
B (4.45 +/- 0.10) 4-Hydroxy-3-methoxy benzoic acid 
C (4.34 +/- 0.10) 3,5-Dimethylbenzoic acid 
D (4.08 +/- 0.10) 3-Hydroxybenzoic acid 
E (4.02 +/- 0.10) 4-Iodobenzoic acid 
F (3.97 +/- 0.10) 4-Chlorobenzoic acid 
G (3.64 +/- 0.10) 3-Cyanobenzoic acid 
H (3.54 +/- 0.10) 4-Cyanobenzoic acid 
I (3.48 +/- 0.10) 3-Nitrobenzoic acid 
J (3.46 +/- 0.10) 3-Bromo-5-iodobenzoic acid 
K (3.42 +/- 0.10) 4-Nitrobenzoic acid 
L (3.27 +/- 0.10) 2-Fluorobenzoic acid 
M (2.97 +/- 0.25) 2-Chlorobenzoic acid 
N (2.77 +/- 0.10) 3,5-Dinitrobenzoic acid 
O (2.34 +/- 0.10) 2,6-Difluorobenzoic acid 
P (2.19 +/- 0.25) 2-Nitrobenzoic acid 
Q (1.93 +/- 0.10) 2-Fluoro-6-iodobenzoic acid 
R (1.69 +/- 0.10) 2,6-Dichlorobenzoic acid 
S (1.60 +/- 0.10) Pentafluorobenzoic acid 
T (1.43 +/- 0.25) 2,4-Dinitrobenzoic acid 
 
The prominent stretches from the IR are summarized in Table 4.4, showing the presence 
of broad OH stretches in the 2500 cm
-1
 and 1900 cm
-1
 regions; the corresponding supramolecular 
yield (calculated as the number of positive hits) is given in the last row to indicate the reactivity. 
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Table 4.3  Summary of prominent IR stretches for the triazole molecules combined with various 
carboxylic acids. 
Acids  
I 
 
II 
 
 
III 
 
IV 
 
V 
 
VI 
 
VII 
A - - - 
2479, 1921, 
1670 
2550, 1889, 
1666 
2417, 1874, 
1666 
2452, 1944, 
1666 
B 
2515, 1831, 
1670 
2542, 1854, 
1670 
- 
2476, 1874, 
1663 
2526, 1862, 
1674 
2503, 1901, 
1666 
2444, 1893, 
1670 
C - - - 
2569, 1901, 
1686 
2562, 1874, 
1682 
2495, 1901, 
1682 
2515, 1921, 
1682 
D - - - 
2522, 1901, 
1694 
2577, 1885, 
1678 
2429, 1854, 
1686 
2522, 1917, 
1694 
E - - - 
2538, 1905, 
1678 
2542, 1909, 
1670 
2542, 1928, 
1666 
2495, 1893, 
1682 
F 
2831, 1866, 
1674 
2507, 1905, 
1706 
- 
2491, 1866, 
1690 
2558, 1924, 
1678 
2542, 1928, 
1674 
2401, 1921, 
1686 
G - - - 
2436, 1881, 
1682 
2581, 1878, 
1682 
2526, 1905, 
1678 
2429, 1889, 
1698 
H 
2823, 1878, 
1682 
2397, 1936, 
1702 
- 
2433, 1897, 
1709 
2554, 1897, 
1690 
2421, 1917, 
1694 
2433, 1897, 
1706 
I 
2468, 1893, 
1694 
2483, 1878, 
1686 
- 
2444, 1905, 
1694 
2526, 1913, 
1686 
2370, 1893, 
1686 
2390, 1917, 
1702 
J - - - 
2479, 1885, 
1690 
2526, 1948, 
1706 
2409, 1881, 
1682 
2401, 1901, 
1682 
K 
2863, 1854, 
1686 
2464, 1881, 
1702 
- 
2425, 1905, 
1682 
2542, 1952, 
1690 
2390, 1913, 
1706 
2397, 1909, 
1682 
L 
2827, 1897, 
1686 
2511, 1897, 
1702 
- 
2468, 1913, 
1706 
2624, 1913, 
1682 
2456, 1905, 
1698 
2472, 1913, 
1698 
M - - - 
2511, 1917, 
1686 
2538, 1944, 
1686 
2476, 1909, 
1706 
2472, 1924, 
1698 
N 
2444, 1975, 
1620 
2534, 1905, 
1694 
- 
2409, 1924, 
1709 
2534, 1889, 
1694 
2448, 1889, 
1706 
2409, 1921, 
1698 
O - 
2401, 1924, 
1686 
- 
2476, 1932, 
1713 
2534, 1952, 
1682 
2476, 1917, 
1709 
2487, 1948, 
1702 
P 
2542, 1936, 
1678 
2483, 1913, 
1706 
- 
2448, 1909, 
1709 
2538, 1924, 
1682 
2452, 1913, 
1706 
2456, 1901, 
1709 
Q 
2487, 1936, 
1709 
2487, 1932, 
1713 
- 
2444, 1905, 
1713 
2483, 1921, 
1709 
2436, 1921, 
1706 
2464, 1924, 
1706 
R 
2495, 1944, 
1709 
2499, 1940, 
1721 
- 
2468, 1921, 
1713 
2491, 1932, 
1717 
2460, 1921, 
1709 
2472, 1940, 
1713 
S 
2499, 1901, 
1717 
2515, 1924, 
1717 
- 
2476, 1913, 
1713 
2436, 1909, 
1717 
2464, 1901, 
1717 
2499, 1924, 
1717 
T 
2526, 1979, 
1713 
2440, 1936, 
1709 
- 
2448, 1932, 
1717 
2530, 1924, 
1713 
2468, 1866, 
1682 
2487, 1956, 
1706 
Supramolecular 
yield (%) 
12/20 = 
60% 
13/20 = 
65% 
0/20 = 
0% 
20/20 = 100% 20/20 = 100% 20/20 = 100% 20/20 = 100% 
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Co-crystals: 
4.3.4 Crystal structure of 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine:bis(3-nitrobenzoic) acid 
(1:2), VII:I2 
The crystal structure of VII:I2 shows a 1:2 ratio between ditopic ligand and carboxylic 
acid. Two predominant interactions are observed. At the pyridine end, a two-point contact exists 
between carboxylic acid and pyridine nitrogen atom, where O-H···N(py) distance is 2.646(4)Å, 
166(2)°; the pyridine C-H interacts with a carbonyl oxygen, and the C-H···O=C distance is 
2.654Å. The ratio of C-O/C=O is 1.06 and the C-N(py)-C angle is 119(3)°, indicating the proton 
remains on the carboxylic acid. On the triazole end, a second acid forms a single point contact 
with the triazole nitrogen atom: O-H···N4(trz) distance is 2.618(12)Å, 167(2)°; the C-N4-C angle 
is 103(5)°. The ratio of C-O/C=O is 1.08, indicating the proton remains on the acid, Figure 4.10.  
 
Figure 4-10 The primary interactions observed in the crystal structure of VII:I2. 
 
4.3.5 Crystal structure of 4-((1H-1,2,4-triazol-1-yl)methyl)pyridine:bis(4-nitrobenzoic) acid 
(1:2), VII:K2 
The crystal structure of VII:K2 also shows a 1:2 ratio between ditopic ligand and 
carboxylic acid. Two predominant interactions are observed. At the pyridine end, a two-point 
contact exists between carboxylic acid and pyridine nitrogen atom, where O-H···N(py) distance 
is 2.659(3)Å, 173(2)°; the pyridine C-H interacts with a carbonyl oxygen, and the C-H···O=C 
distance is 2.557Å. The ratio of C-O/C=O is 1.08 and the C-N(py)-C angle is 118(2)°, indicating 
the proton remains on the carboxylic acid. On the triazole end, a second acid forms a two point 
contact with the triazole base. The triazole nitrogen atom interacts with a carboxylic acid, and a 
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C-H from triazole interacts with a carbonyl oxygen atom from the acid, respectively: O-
H···N4(trz) distance is 2.673(3)Å, 177(3)°; C-H···O=C distance is 2.661Å. The C-N4-C angle is 
103(2)° and the ratio of C-O/C=O is 1.08, indicating the proton remains in the carboxylic acid, 
Figure 4.11.  
 
 
Figure 4-11 The primary interactions observed in the crystal structure of VII:K2. 
Salt: 
4.3.6 Crystal structure of 4-((1H-1,2,3-triazol-1-yl)methyl)pyridinium:3,5-dinitrobenzoate:3,5-
dinitrobenzoic acid hydrate (1:2:1), V:N2:H2O 
The crystal structure of V:N2:H2O shows proton transfer from a carboxylic acid to a 
pyridine nitrogen atom resulting in a hydrated salt, with a charge-assisted N
+
-H···
-
O distance of 
2.5810(18)Å, 176(18)°. The C-N(py)-C bond angle is 121(14)° and the C-O
-
/C-O
-
 carboxylate 
bond ratio is 1.02, indicating the carboxylic acid proton has been transferred to the pyridine 
nitrogen atom. The triazole nitrogen atom (N3) interacts with water via O-Hw···N3(trz) hydrogen 
bonds, where the O-Hw···N3(trz) distance is 2.7696(19)Å, 177(2)°. The carboxylate interacts 
with water through charge-assisted O-Hw···
-
O interactions, where the O-Hw···
-
O-C distance is 
2.7276(16)Å, 171(2)°. A neutral acid incorporates itself into the crystal structure via O-H···Ow 
interactions, where the O-H···Ow distance is 2.5364(16)Å, 172(2)°, Figure 4.12.  
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Figure 4-12 The primary interactions observed in the crystal structure of V:N2:H2O. 
 
 4.4 Discussion 
4.4.1 What do charge calculations tell us about where binding preferences should be?  
Charge calculations were performed on the library of molecules I-VII, Figure 4.13. 
 
 
Figure 4-13 Triazole (I-III) and triazole/pyridine asymmetric ditopic molecules (IV-
VII). 
 
The AMI charges for both N1-H on I and II are +202 and +201, respectively, indicating 
very small differences. However, there is a significant difference between the nitrogen atoms on 
the two triazole molecules. N2(trz) -217 kJ/mol, and N3(trz) -277 kJ/mol, respectively. In the case 
of II, the same trend is observed; N2(trz) is -216 kJ/mol, and N4(trz) is -280 kJ/mol, respectively. 
The difference is almost the same as in I. This result indicates that in both molecules, I and II, 
N2(trz) should not be the preferred hydrogen-bond acceptor site and that both N3(trz) and N4(trz) 
carry a higher charge and should therefore be where a hydrogen-bond donor (e.g. carboxylic 
acid) would prefer to interact. 
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When a strongly electron withdrawing nitro group (R-NO2) is added, III, the electrostatic 
charges change drastically. The N1-H hydrogen atom goes to +271 kJ/mol, a +70 kJ/mol 
difference from I and II. Furthermore, the charge on N2(trz) drops significantly to -165 kJ/mol, 
as does N4(trz) to -238 kJ/mol.  
When a third acceptor site is added to the backbone of the triazole molecule via a 
methylene bridge, there are no significant differences between the N(py) acceptor site compared 
to either N3(trz) or N4(trz). In IV, the charge on the N(py) is -260 kJ/mol and N3(trz) is -275 
kJ/mol. The charge on N2(trz) in this case is -200 kJ/mol, even lower than I. The values indicate 
there may not be a significant difference in binding preference for an incoming hydrogen-bond 
donor. In the case of V, the charge on N(py) is -270 kJ/mol and N3(trz) is -271 kJ/mol, 
respectively, indicating both sites should be equally attractive for an incoming acid. 
In VI and VII, respectively, both molecules show a similar trend where N4(trz) carries a 
higher charge than N(py). In VI, the values are -270 kJ/mol for N(py) and -288 kJ/mol for 
N4(trz). In VII, the values are -268 kJ/mol for N(py) and -280 kJ/mol for N4(trz). For VI and 
VII, both values of N2(trz) are around -200 kJ/mol. The results for this set of molecules would 
predict the binding to occur at N4(trz), which carries a higher charge over the N(py) in both 
cases.  
 
4.4.2 Can we determine co-crystal or salt formation from the IR data? 
The data from the IR screening show that both triazoles I and II have very similar 
reactivity when combined with various carboxylic acids. In the case of I, a 60% supramolecular 
yield was obtained from the solvent assisted grinding experiments with twenty acids of varying 
strength (12 positive hits / 20 total reactions). In II, a 65% yield was obtained upon screening 
with the same group of acids. The results are not surprising considering the charges on the 
strongest hydrogen bond acceptor site are nearly identical. The result is consistent with the 
screening work from Chapter 2 with pyrazole (supramolecular yield of 55%), which carries a 
slightly lower charge on the primary acceptor, Table 4.4. 
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Table 4.4  Summary of charges on pyrazole and the triazole molecules. 
Molecule 
   
Charge on best acceptor 
(kJ/mol) 
-251 -277 -280 
Supramolecular yield 
(%) 
55% 60% 65% 
 
On the other hand, the results for III (the nitro analog) are completely different. No 
reactions were observed, and despite the large increase in charge on the N1-H (+70 kJ/mol) from 
I and II, the supramolecular yield decreases, indicating the balance between an increase in 
charge on the hydrogen and a lowering of charge on both nitrogen acceptors is not sufficient to 
drive any supramolecular reaction, Table 4.4.  
When a pyridine moiety is introduced and both pyridine and triazole are part of the same 
molecular backbone, the supramolecular yield increases. This indicates that pyridine is a better 
acceptor to triazole, despite the two having similar charges. The results follow the same trend as 
noted in Chapter 3; introducing a pyridine moiety (and subsequently a higher charge on the 
acceptor site) to the pyrazole backbone also gave an increased supramolecular yield, Table 4.5. 
Table 4.5  Summary of the results obtained from different chapters. 
Chapter # Ch. 2 Ch. 3 Ch. 4 
Molecule 
 
 
 
 
Supramolecular 
yield (%) 
55% 100% 60% 100% 
 
The increase in supramolecular reactivity for the pyrazole case can be explained by the 
fact that adding a group with a higher charge increases the supramolecular yield, but the same 
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argument does not hold true for the triazole case (since the triazole nitrogens N3(trz) and N4(trz) 
actually carry the same or higher charge in molecules I, II, IV-VII).  
The additional C-H···O=C interaction present in carboxylic acid···pyridine synthons may 
push the balance to favor the pyridine side; triazole does have an aromatic C-H group to make a 
C-H···O=C interaction, but the geometry around that site is very different and therefore may not 
stabilize the interaction as much as the two-point contact to pyridine. 
4.4.3 Can we group the interactions in the co-crystals and salts from the single crystal data? 
Two co-crystals and one salt were obtained, and the co-crystals show structural 
consistency. The salt, on the other hand, displayed unpredictable chemical composition and 
structural landscape, consistent with the results obtained from Chapters 2 and 3.   
4.4.3.1 Co-crystals 
Both co-crystals obtained (2/2) display the same 1:2 ratio between ditopic molecule and 
carboxylic acid. The structures both show the expected O-H···N(py) interaction, as well as an O-
H···N4(trz) interaction, Figure 4.14. 
 
Figure 4-14 Primary interactions observed in the co-crystals obtained. 
 
4.4.3.2 Salt 
In the crystal structure of V + N, the proton is transferred to the pyridine nitrogen atom 
over the two triazole acceptor sites, N2(trz) and N3(trz). Both N(py) and N3(trz) carry nearly 
identical charges, but the proton is transferred to the site with the lower pKb value, N(py), Figure 
4.15. 
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Figure 4-15 Proton transfer to the N(py) site in the salt formed between V and N. 
 
So, how do we explain the proton being transferred to the N(py) and not the N3(trz)? A 
search of the CSD of other ditopic molecules containing pyridine and triazole shows the 
following results. First, there are no other structures in the database containing the asymmetric 
ditopic molecule presented. Second, there are a number of structures, (ABIYEP, BIYROQ, 
CUVMEM, CUVMIQ, CUVMOW, JINQAZ, KASMEW, VABLOZ) where proton transfer 
occurs to the pyridine 100% of the time over the triazole, Table 4.6. 
Table 4.6  Summary of relevant structures 
CSD code ABIYEP BIYROQ FOPHEY FOPHIC IKALUC 
Proton transfer N(py) N(py) N(py) N(py) N(py) 
 
CIPCUA and UGARUP are two examples of a triazole being protonated instead of 
pyridine, which we would not predict based on pKb values. ZAPMIO protonation occurs at N2 
over N4.  
This result is not surprising, considering the pyridine has a lower pKb value compared to 
the 1,2,4-triazole. The data also indicate that the pyridinium cation is more stable than the 
triazolium cation. When proton transfer takes place, it is not uncommon to find water or neutral 
molecules in the crystalline lattice. Carboxylates are very good hydrogen-bond acceptors, and 
show a propensity to attract a wide variety of hydrogen-bond donors. This is also consistent with 
Chapters 2 and 3, where the formation of salts displays unpredictable landscape and topology.12 
 
In summary, 
I. Triazole can compete with pyridine for carboxylic acids. 
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II. The screening results give the same success rates for the triazoles (60-65%) 
compared to pyrazole (55-65%) from Chapter 2; the asymmetric ditopic triazole/ 
pyridine gives similar success rates (100%) as ditopic pyrazole/pyridine (90-
100%) from Chapter 3. 
III. Carboxylic acids can bind equally well to N(py) or N4(trz) and display binding 
motifs 1 and 10 from Figure 4.7, shown in Figure 4.16 below. 
 
 
Figure 4-16 Two groups of interactions, 1 and 10, observed from the potential interactions listed 
in Figure 4.7. 
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Halogen-bonding (XB) with ditopic pyridine/pyrazole: Are Chapter 5 - 
halogen-bonds competitive with hydrogen-bonds? 
 5.1 Introduction 
The halogen-bond (XB), a term first used by J. M. Dumas1 to describe complexes formed 
between CCl4, CBr4, SiCl4, and SiBr4 with pyridine, anisole, tetrahydrofuran, tetrahydropyran, 
and di-n-butylether in organic solvents, is a non-covalent intermolecular interaction between an 
electronegative atom like nitrogen or oxygen (Lewis base) and a covalently bound halogen 
atom.2 The XB has emerged as a reliable tool for the crystal engineer to design functional 
materials3 and supramolecular complexes and networks4 with predictable topologies5, ranging 
from sensors6 to applications in medicinal chemistry and biology.7  
Halogen bonded ‘addition complexes’ have been known since the mid-19th century, and 
were first reported by Guthrie8 in 1863 where he described the interaction of a Lewis base with a 
dihalogen (H3N···I2). Over thirty years later in 1896, Remsen and Norris
9 followed that work by 
studying amines and adducts formed with bromine and chlorine. XB investigations in the early 
20
th
 century began with the work of Benesi and Hildebrand10 involving spectrophotometric 
investigation of iodine interactions with aromatic hydrocarbons (benzene). Hassel11 worked on 
crystalline compounds formed between various Lewis bases and dihalogens in the 1950’s and 
1960’s, for which he was subsequently jointly awarded the Nobel prize with Derek H. R. Barton 
in 1969.12 The early work of Bent13, Laurence14, Pennington15, and Klemperer16 (to name a few) all 
enabled the field to see substantial growth before the beginning of the 21
st
 century. Since then, 
Metrangolo and Resnati have led the way in understanding halogen bonding and its applications 
in the field of crystal engineering.17  
The directionality of the XB is attributed to the presence of a sigma hole18, which is an 
area of positive charge on an outer ‘electron depleted’ p orbital on iodine.19 The name is a result 
of the sigma hole being an extension of the C-I sigma bond between carbon and iodine. A simple 
picture of this phenomenon is illustrated using carbontetrafluoride, where replacing one of the 
fluorine atoms with a halogen, beginning with chlorine, bromine and iodine creates a positive 
electrostatic tip on the halogen atom. The electron withdrawing effects induced by the fluorine 
atoms on the halogen atom increases going from chlorine to bromine to iodine; the most 
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pronounced effect is felt by iodine, which displays the biggest sigma hole (largest blue lobe), 
Figure 5.1. 
 
 
Figure 5-1 Increase in the size of the sigma hole. Red indicates areas of negative charge; 
blue indicates areas of positive charge (figure adapted from reference).20 
 
Iodine has a larger sigma hole than either bromine or chlorine, and the electrostatic 
potential around the end of the iodine (and bromine, to a lesser extent) is positive and carries a 
positive quadrupole moment.21 As a result, fluorinated iodine and fluorinated bromine are 
commonly used as XB donors. A simple schematic of a XB bond between a nitrogen atom 
electron lone pair (Lewis base) and a ‘sigma hole’ from an iodine atom is shown in Figure 5.2. 
 
Figure 5-2 Halogen-bonding (XB) interaction between nitrogen and iodine. 
 
Why has XB become so popular among crystal engineers and, can it compete with 
hydrogen bonds (HB)? First, halogen bonding is both strong (in a non-covalent context) and 
directional22, with energies on the order of 20-160 kJ/mol.23 Legon et al.24 has shown that these 
energies are similar to those observed for hydrogen bonds. There is strong evidence to suggest 
that XB’s are competitive with HB’s,25 and XB’s have even been claimed to represent “a world 
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parallel to hydrogen bonding”26 and can be used to design useful materials, from polymeric liquid 
crystals27, inorganic coordination complexes28, and supramolecular gels.29 
Crystal engineers have recognized XB as a useful tool for the assembly of various solid-
state architectures containing both aromatic and non-aromatic perfluoroalkanes. Some examples 
of the use of iodoperfluoroalkanes for halogen-bond driven co-crystal synthesis30
,31,32 is shown 
below, Figure 5.3.  
 
 
Figure 5-3 Halogen-bonding (XB) interaction between IPFA’s and aromatic and 
aliphatic nitrogen compounds (figure adapted from reference).33 
 
Despite the fact that the examples in Figure 5.3 all contain I···N(py) or I···N(amine) 
halogen bonds, it has yet to be established if halogen bonds to a pyrazole nitrogen atom, N(pyz), 
can be formed. In fact, a recent search of the CSD shows no hits for XB’s to a pyrazole nitrogen 
atom. Furthermore, it is important to establish if XB’s and HB’s may be used together to give 
reliable and predictable synthons used for making supramolecular structures.  
Thus, if halogen bonds are electrostatic in nature, akin to hydrogen bonds, then there 
should be similarities when forming XB’s to pyridine and pyrazole. Since we already established 
that reliable hydrogen bonds can be formed to both pyridine and pyrazole nitrogen atoms from 
the work in Chapter 3, we wanted use the same methodology to screen a library of XB donors 
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with pyrazole and pyridine/pyrazole based acceptor molecules. Density functional theory (DFT) 
calculations will replace AM1 because a higher level of theory is required for calculating 
electrostatic potentials of halogen-containing molecules. The resulting solids from the grinding 
experiments were analyzed using IR spectroscopy, and each peak from the XB donor was 
carefully scrutinized to determine any shifts. Those solids which gave a reaction were then 
converted to single crystal experiments in an effort to generate single crystals. From the single 
crystal data, inferences about binding preferences were made, following the same process used in 
Chapters 2-4. A flowchart displaying the method is shown in Figure 5.4. 
 
Figure 5-4 Flowchart for determining a correlation between charge calculations and 
single crystal results. 
 
This chapter will attempt to answer the following questions: 
 
I. Do iodine-based XB donors show a higher success rate than bromine-based XB 
donors when screened with N(pyz) and N(py) acceptor molecules? Hypothesis: 
Iodine donors will show a higher success rate compared to bromine. CSD results 
indicate that iodine is better suited for XB interactions with Lewis bases.  
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II. Is the pyrazole nitrogen atom, N(pyz), a suitable halogen-bond acceptor? 
Hypothesis: The pyrazole nitrogen atom, N(pyz), will be a suitable XB acceptor. 
III. Are halogen bonds competitive with hydrogen bonds? Hypothesis: XB to N(pyz) 
or N(py) should be able to compete with N-H hydrogen bonds to the acceptor 
sites. The following XB donors and acceptors will be used, Tables 5.1 and 5.2. 
 
Table 5.1 Library of halogen-bond (XB) acceptors used in the screening. 
Name Abbreviation Structure 
1H-Pyrazole P 
 
3,5-Dimethyl-1H-pyrazole DMP 
 
4-Iodo-3,5-dimethyl-1H-
pyrazole 
DMP-I 
 
2-(1H-Pyrazol-4-yl)pyridine 2 
 
3-(1H-Pyrazol-4-yl)pyridine 3 
 
4-(1H-Pyrazol-4-yl)pyridine 4 
 
 
 
 
 
Table 5.2 Library of halogen bond (XB) donors used in the screening. 
 Name Abbreviation Structure 
 
 
 
Iodine-based 
XB donors 
 
Iodobenzene IB 
 
Iodopentafluorobenzene IPFB 
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1,4-diiodotetrafluorobenzene DITFB 
 
1,2-diiodoterafluorobenzene 1,2-DITFB 
 
1,2-diiodotetrafluoroethane 1,2-DITFE 
 
1,4-diiodooctafluorobutane 1,4-DIOFB 
 
1,6-diiodoperfluorohexane 1,6-DIPFH 
 
2,2',3,3',5,5',6,6'-octafluoro-
4,4'-diiodo-1,1'-biphenyl 
4,4’-DIOFBP 
 
 
 
 
bromine-
based XB 
donors 
bromobenzene BB 
 
bromopentafluorobenzene BPFB 
 
1,4-dibromotetrafluorobenzene DBTFB 
 
1,2-dibromotetrafluorobenzene 1,2-DBTFB 
 
1,3-dibromotetrafluorobenzene 1,3-DBTFB 
 
2,2',3,3',5,5',6,6'-octafluoro-
4,4'-dibromo-1,1'-biphenyl 
4,4’-DBOFBP 
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 5.2 Experimental 
5.2.1 Charge calculations 
Molecular electrostatic potential (MEP) surface charge calculations were performed 
using Spartan (Wavefunction, Inc., Irvine, CA). The molecules were optimized using DFT at the 
B3LYP/6-311+G** level. 
5.2.2 Synthesis of 3-(1H-pyrazol-4-yl)pyridine:1,4-diiodooctafluorobutane (4:1), 34:1,4-
DIOFB 
To a vial, 1,4-diiodooctafluorobutane (65.5mg, 0.1443mmol) was added followed by 
0.5mL of methanol. Next, 3-(1H-pyrazol-4-yl)pyridine (21.0mg, 0.1443mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
rods were obtained after a few days. Mp: 113-115°C. 
5.2.3 Synthesis of 3-(1H-pyrazol-4-yl)pyridine:1,6-diiodoperfluorohexane (4:1), 34:1,6-DIPFH 
To a vial, 1,6-diiodoperfluorohexane (18.3mg, 0.033mmol) was added followed by 
0.5mL of methanol. Next, 3-(1H-pyrazol-4-yl)pyridine (4.8mg, 0.033mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
rods were obtained after a few days. Mp: 107-108°C. 
5.2.4 Synthesis of 4-(1H-pyrazol-4-yl)pyridine:1,2-diiodotetrafluoroethane (2:1), 42:1,2-
DITFE 
To a vial, 1,2-diiodotetrafluoroethane (51.8mg, 0.146mmol) was added followed by 
0.5mL of methanol. Next, 4-(1H-pyrazol-4-yl)pyridine (21.0mg, 0.146mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Bronze 
plates were obtained after a few days. Mp: turns opaque at 90°C. 
5.2.5 Synthesis of 4-(1H-pyrazol-4-yl)pyridine:1,4-diiodooctafluorobutane (5:3), 45:1,4-
DIOFB3 
To a vial, 1,4-diiodooctafluorobutane (51.6mg, 0.114mmol) was added followed by 
0.5mL of methanol. Next, 4-(1H-pyrazol-4-yl)pyridine (16.5mg, 0.114mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
prisms were obtained after a few days. Mp: turns opaque at 85°C. 
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5.2.6 Synthesis of 2-(1H-pyrazol-4-yl)pyridine:1,4-diiodotetrafluorobenzene (1:1), 2:1,4-
DITFB 
To a vial, 1,4-diiodotetrafluorobenzene (12.5mg, 0.031mmol) was added followed by 
0.5mL of methanol. Next, 2-(1H-pyrazol-4-yl)pyridine (4.3mg, 0.030mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
prisms were obtained after a few days. Mp: 140-143°C. 
5.2.7 Synthesis of 3-(1H-pyrazol-4-yl)pyridine:1,4-diiodotetrafluorobenzene (1:1), 3:1,4-
DITFB 
To a vial, 1,4-diiodotetrafluorobenzene (12.5mg, 0.031mmol) was added followed by 
0.5mL of methanol. Next, 3-(1H-pyrazol-4-yl)pyridine (4.4mg, 0.030mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
prisms were obtained after a few days. Mp: 135-140°C. 
5.2.8 Synthesis of 4-(1H-pyrazol-4-yl)pyridine:1,4-diiodotetrafluorobenzene (2:1), 42:1,4-
DITFB 
To a vial, 1,4-diiodotetrafluorobenzene (10.2mg, 0.0254mmol) was added followed by 
0.5mL of methanol. Next, 4-(1H-pyrazol-4-yl)pyridine (3.7mg, 0.0254mmol) was added to the 
same vial. The solution was heated and left for slow evaporation (loose screw cap). Colorless 
rods were obtained after a few days. Mp: 101-105°C. 
5.2.7 IR spectroscopy 
Infrared spectra were collected on a Thermo Scientific Nicolet 380 FT-IR using a ZnSe 
crystal. The solids obtained from solvent-assisted grinding experiments (and solution-based 
experiments) were analyzed by placing the solid directly on the crystal and performing 128 
scans. Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected. 
 5.3 Results 
5.3.1 DFT calculations 
Density functional theory (DFT) calculations were made in order to rank the strengths of 
XB acceptor and donor molecules, Tables 5.3 and 5.4. 
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Table 5.3 Summary of DFT charges (kJ/mol) on the pyridine nitrogen atom (N(py), red), 
pyrazole nitrogen atom (N(pyz), orange) and pyrazole N-H hydrogen atom (blue). 
  
 
   
N(pyz) = -185 
N-H = +239 
N(pyz) = -195 
N-H = +225  
N(pyz) = -195 
N-H = +225 
N(pyz) =  -178 
N(py) = -144 
N-H = +245 
N(pyz) = -168 
N(py) = -191 
N-H = +271 
N(pyz) =  -161 
N(py) = -193 
N-H = +274 
 
Table 5.4 Summary of charges for the iodine donors 
Iodine donors 
Name Abbreviation Structure Charges 
Iodobenzene IB 
 
+103 
Iodopentafluorobenzene IPFB 
 
+166 
1,4-
Diiodotetrafluorobenzene 
DITFB 
 
+169 
1,2-
Diiodoterafluorobenzene 
1,2-DITFB 
 
+163 
1,2-
Diiodotetrafluoroethane 
1,2-DITFE 
 
+164 
1,4-
Diiodooctafluorobutane 
1,4-DIOFB 
 
+171 
1,6-
Diiodoperfluorohexane 
1,6-DIPFH 
 
+169 
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2,2',3,3',5,5',6,6'-
Octafluoro-4,4'-diiodo-
1,1'-biphenyl 
4,4’-DIOFBP 
 
- 
 
Table 5.5 Summary of charge for the bromine donors 
Bromine 
donors 
Name Abbreviation Structure Charges 
Bromobenzene BB 
 
+63 
Bromopentafluorobenzene BPFB 
 
+143 
1,4-
Dibromotetrafluorobenzene 
DBTFB 
 
+140 
1,2-
Dibromotetrafluorobenzene 
1,2-DBTFB 
 
+137 
1,3-
Dibromotetrafluorobenzene 
1,3-DBTFB 
 
+140 
2,2',3,3',5,5',6,6'-
Octafluoro-4,4'-dibromo-
1,1'-biphenyl 
4,4’-DBOFBP 
 
+142 
 
5.3.2 IR spectroscopy 
A library of six XB acceptor molecules containing pyrazole or pyrazole/pyridine (Table 
5.1) were screened with fourteeen halogen-bond donor molecules containing both activated and 
unactivated (as control) iodine and bromine, Table 5.2. The combinations which gave a reaction, 
based on shifts in the XB donor bands, were converted to solution based experiments. The values 
of the bands after the grinding are tabulated in Table 5.6. 
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Table 5.6 Summary of 84 solvent-assisted grinding experiments. XB donors are listed in 
the left hand column; XB acceptors are top row. 
XB donors Pyrazole DMP DMP-I 2 3 4 
Iodobenzene 
(1571, 1471, 
1438, 1058, 
1014, 997, 727, 
684) 
no rxn no rxn no rxn no rxn no rxn no rxn 
IPFB (1509, 1489, 
1081, 1001, 974, 
805) 
no rxn no rxn no rxn 
(1512, 1482, 
1088, 989, 957, 
779) 
(1502, 1477, 
1079, 995, 971, 
795) 
(1504, 1481, 
1073, 1001, 969, 
808) 
1,4-DITFB (1459, 
1430, 1355, 
1215, 986, 969, 
941, 759) 
no rxn no rxn no rxn 
(1456, 1430, 
1351, 1211, 982, 
967, 939, 750) 
(1455, 1427, 
1356, 1211, 973, 
935, 756) 
(1452, 1430, 
1355, 1217, 983, 
958, 934, 759) 
1,2-DITFB (1490, 
1439, 1110, 
1024, 814, 773) 
no rxn 
(1483, 1420, 
1304, 1105, 
1024, 1008, 777) 
no rxn 
(1482, 1435, 
1101, 1021, 812, 
776) 
(1482, 1433, 
1107, 1021, 812, 
772) 
(1481, 1437, 
1100, 1016, 807, 
763) 
1,2-DITFE (1206, 
1153, 1100, 973, 
834, 694, 636) 
no rxn 
(1201, 1127, 
1092, 975, 802, 
698) 
(1198, 1163, 
1074, 968, 832, 
681) 
(1202, 1136, 
974, 827, 701) 
(1200, 1149, 
1077, 966, 827, 
698) 
(1201, 1158, 
1092, 972, 833, 
691, 633) 
1,4-DIOFB (1192, 
1134, 1103, 
1088, 1039, 888, 
764, 718, 696, 
634) 
no rxn no rxn 
(1161, 1103, 
1076, 1036, 886, 
764, 714, 689) 
(1197, 1116, 
1075, 1038, 889, 
776, 741, 703, 
676) 
(1193, 1133, 
1108, 1087, 
1041, 889, 764, 
723, 704, 633) 
(1176, 1124, 
1045, 868, 757, 
716, 687, 629) 
1,6-DIPFH (1199, 
1141, 1086, 927) 
(1214, 1131, 1091, 
923) 
(1208, 1145, 
1086, 838) 
(1164, 1128, 
1076, 909) 
(1216, 1129, 
1081, 931) 
(1210, 1148, 
1089, 928) 
(1209, 1132, 
1078, 920) 
4,4’-DPDIOF 
(1471, 1219, 984, 
975, 954, 716) 
no rxn no rxn no rxn no rxn no rxn no rxn 
Success rate (%) 1/8 = 12.5% 3/8 = 37.5% 3/8 = 37.5% 6/8 = 75% 6/8 = 75% 6/8 = 75% 
Bromobenzene 
(1575, 1472, 
1440, 1067, 
1018, 1000, 902, 
730, 682, 669) 
no rxn no rxn no rxn no rxn no rxn no rxn 
BPFB (1499, 
1091, 1005, 978, 
834, 615) 
no rxn no rxn no rxn 
(1523, 1089, 
990, 956, 827) 
(1514, 1030, 
947, 793) 
(1512, 1103, 
1001, 955, 832) 
1,4-DBTFB (1494, 
1449, 1235, 990, 
954, 788 
no rxn 
14823, 1420, 
1308, 1027, 
1008, 777) 
no rxn no rxn no rxn no rxn 
1,2-DBTFB (1499, 
1457, 1118, 
1035, 847, 802) 
(1500, 1464, 1134, 
1029, 837, 752) 
(1483, 1462, 
1149, 1028, 841, 
779) 
(1463, 1407, 
1075, 1033, 765) 
(1478, 1431, 
1117, 1024, 829, 
775) 
(1486, 1448, 
1151, 1029, 838, 
794) 
(1513, 1428, 
1101, 1027, 834, 
813) 
1,3-DBTFB (1484, 
1446, 1082, 893, 
743, 702) 
no rxn 
(1421, 1304, 
1153, 1027, 
1008, 840, 778, 
737) 
(1573, 1408, 
1304, 1161, 
1075, 1033, 765) 
no rxn no rxn 
(1513, 1428, 
1103, 899, 683, 
660) 
4,4’-DPDBOF 
(1467, 1238, 993, 
958, 866, 720) 
no rxn no rxn no rxn no rxn no rxn no rxn 
Success rate (%) 1/6 = 16.7% 3/6 = 50% 2/6 = 33.3% 2/6 = 33.3% 2/6 = 33.3% 3/6 = 50% 
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5.3.3 Crystal structure of 3-(1H-pyrazol-4-yl)pyridine:1,4-diiodooctafluorobutane (4:1), 
34:1,4-DIOFB 
The crystal structure of 34:1,4-DIOFB displays a combination of hydrogen and halogen 
bonds. A hydrogen bond forms between the pyrazole nitrogen atom and the pyrazole N-H proton 
to make a catemer on both sides: on one side, the N-H···N(pyz) distance is 2.8027(16), angle is 
178(17)°; on the second side, the N-H···N(pyz) distance is 2.9385(15)Å, angle is 161(16)°. A 
halogen bond occurs between the pyridine nitrogen atom and iodine atom, giving a C-I···N 
distance of 2.781Å and a C-I···N angle of 173°, Figure 5.5  
 
Figure 5-5 Primary interactions in the crystal structure of 34:1,4-DIOFB. 
5.3.4 Crystal structure of 3-(1H-pyrazol-4-yl)pyridine:1,6-diiodoperfluorohexane (4:1), 
34:1,6-DIPFH 
The crystal structure of 34:1,6-DIPFH displays a combination of hydrogen and halogen 
bonds. A hydrogen bond occurs between the pyrazole nitrogen atom and the pyrazole N-H 
proton to make a catemer on both sides: on one side, the N-H···N(pyz) distance is 2.800(3)Å, 
angle is 170(3)°; on the second side, the N-H···N(pyz) distance is 2.942(3)Å, angle is 162(2)°. A 
halogen bond occurs between the pyridine nitrogen atom and iodine atom, giving a C-I···N 
distance of 2.786Å and a C-I···N angle of 175°, Figure 5.6  
 
Figure 5-6 Primary interactions in the crystal structure of 34:1,6-DIPFH. 
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5.3.5 Crystal structure of 4-(1H-pyrazol-4-yl)pyridine:1,2-diiodotetrafluoroethane  (2:1), 
42:1,2-DITFE 
The crystal structure of 42:1,2-DITFE shows 1-D chains connected via N-H···N(py) 
hydrogen bonds. The N-H···N(py) distance is 2.838(3)Å and the N-H···N(py) angle is 168(3)°. 
The N-H proton remains on the pyrazole as evidenced by the C-N(py)-C bond angle of 116(19)°. 
The chains are connected via C-I···N(pyz) halogen bonds; C-I···N(pyz) distance is 2.839Å and 
the C-I···N(pyz) angle is 173°, Figure 5.7. 
 
Figure 5-7 Primary interactions in the crystal structure of 42:1,2-DITFE. 
5.3.6 Crystal structure of 4-(1H-pyrazol-4-yl)pyridine:1,4-diiodooctafluorobutane  (5:3), 
45:1,4-DIOFB3 
The crystal structure of 45:1,4-DIOFB3 displays a combination of hydrogen and halogen 
bonds. Two sets of hydrogen bonds occur. In the first set, a hydrogen bond occurs between the 
pyridine nitrogen atom and the pyrazole N-H proton; the N-H···N(py) distance is 3.195(12)Å 
and the N-H···N(py) angle is 165(3)°. The proton remains on the pyrazole as evidenced by the 
C-N(py)-C bond angle of 119(9)°. In the second set, a hydrogen bond occurs between the pyrazole 
nitrogen atom and the pyrazole N-H proton; the N-H···N(pyz) distance is 2.886(13) Å and gives 
an angle of 176(3)°. There are three sets of halogen bonds. In the first set, a pyridine nitrogen 
atom interacts with an iodine atom; C-I1···N(py) distance is 2.743Å and the C-I1···N(py) angle is 
177°; in the second set, C-I2···N(py) distance is 2.758Å and the C-I2···N(py) angle is 174°; in 
the third set, the pyrazole nitrogen atom interacts with an iodine atom, giving a C-I3···N(pyz) 
distance is 2.845Å and the C-I3···N(pyz) angle is 174°, Figure 5.8. 
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Figure 5-8 Primary interactions in the crystal structure of 45:1,4-DIOFB3. 
 
5.3.7 Crystal structure of 2-(1H-pyrazol-4-yl)pyridine:1,4-diiodootetrafluorobenzene (1:1), 
2:1,4-DITFB 
The crystal structure determination of 2:1,4-DITFB displays a supermolecule formed by 
the combination of hydrogen and halogen bonds. A hydrogen bond occurs between the pyridine 
nitrogen atom and pyrazole N-H proton, where the N-H···N(py) distance is 2.872(3)Å and the N-
H···N(py) angle is 159°. The proton remains on the pyrazole as evidenced by the C-N(py)-C bond 
angle of 118(2)°. A halogen bond occurs between the pyrazole nitrogen atom and iodine atom, 
giving a C-I···N(pyz) distance of 2.799Å and a C-I···N(py) angle of 177°. The second iodine 
atom shows no short or long range contacts, Figure 5.9. 
 
Figure 5-9 Primary interactions in the crystal structure of 2:1,4-DITFB. 
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5.3.8 Crystal structure of 3-(1H-pyrazol-4-yl)pyridine:1,4-diiodootetrafluorobenzene (1:1), 
3:1,4-DITFB 
The crystal structure determination of 3:1,4-DITFB displays a supermolecule formed by 
the combination of hydrogen and halogen bonds. A hydrogen bond occurs between the pyridine 
nitrogen atom and pyrazole N-H proton, where the N-H···N(py) distance is 2.830(4)Å and the N-
H···N(py) angle is 174(4)°. The N-H proton remains on the pyrazole as evidenced by the C-
N(py)-C bond angle of 118(3)°. A halogen bond occurs between the pyrazole nitrogen atom and 
iodine atom, giving a C-I···N(pyz) distance of 2.738Å and a C-I···N(py) angle of 174°. The 
second iodine atom shows no short or long range contacts, Figure 5.10. 
 
Figure 5-10 Primary interactions in the crystal structure of 3:1,4-DITFB. 
 
5.3.9 Crystal structure of 4-(1H-pyrazol-4-yl)pyridine:1,4-diiodootetrafluorobenzene (2:1), 
42:1,4-DITFB 
The crystal structure determination of 42:1,4-DITFB displays a chain formed by 
hydrogen and halogen bonds. A hydrogen bond occurs between the pyrazole nitrogen atom and 
the N-H proton, where the pyrazole forms a catemer; the N-H···N(pyz) distance is 2.979(2)Å 
and the N-H···N(pyz) angle is 168(3)°. The halogen bond occurs between the pyridine nitrogen 
atom and iodine atom, giving a C-I···N(py) distance of 2.806Å and a C-I···N(py) angle of 179°, 
Figure 5.11. 
 
Figure 5-11 Primary interactions in the crystal structure of 42:1,4-DITFB. 
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 5.4 Discussion 
5.4.1 What do the DFT calculations tell us about ranking the acceptors and donors? 
From the DFT calculations, it is possible to rank the strengths of the XB acceptors and 
donors, and formulate hypotheses regarding binding preferences.  
First, the XB acceptors contain two possible binding sites, N(py) and N(pyz). The DFT 
calculations for the pyrazole molecules used (P, DMP, and DMP-I) all show the pyrazole 
nitrogen atom, N(pyz), to be similar in value, ranging from -185 kJ/mol (for P) to -195 kJ/mol 
(for DMP and DMP-I). These values indicate that the three pyrazole molecules should display 
similar reactivity when combined with various XB donor molecules. 
When a pyridine moiety is introduced in ditopic molecules 2, 3, and 4, the charge on the 
N(pyz) is lowered in each case. In 2, the charge drops to -178 kJ/mol, whereas in 3 and 4 the 
charge lowers to -168 kJ/mol and -161 kJ/mol, respectively. The values indicate the addition of a 
pyridine moiety withdraws electron density from the N(pyz), and thereby lowers its charge. On 
the other hand, the charge on the N(py) site shows that in ditopic 2 the N(pyz) outranks the 
N(py), -178 kJ/mol vs. -144 kJ/mol. The pyridine nitrogen atom, being in the 2 position, is 
sterically hindered compared to the 3 and 4 isomers, and as a result the charge is less than the 
pyrazole nitrogen atom. On the other hand, the N(py) outranks the N(pyz) in 3 and 4. For 3, the 
values are -191 kJ/mol vs. -168 kJ/mol. For 4, the values are -193 kJ/mol vs. -161 kJ/mol. It is 
noteworthy that the charge on the N(py) in 3 and 4 differs by only 2 kJ/mol, Table 5.7. 
 Table 5.7 Summary of charges on the pyrazole and pyrazole/pyridine XB acceptor 
molecules. 
 
P 
 
DMP 
 
DMP-I  
2 
 
3 
 
4 
N(pyz) = -185 
N-H = +239 
N(pyz) = -195 
N-H = +225  
N(pyz) = -195 
N-H = +225 
N(pyz) =  -178 
N(py) = -144 
N-H = +245 
N(pyz) = -168 
N(py) = -191 
N-H = +271 
N(pyz) =  -161 
N(py) = -193 
N-H = +274 
104 
 
When ranking the XB donors in the system, it is clear that the iodine donors carry higher 
charges then bromine donors. The range for the iodine donors is 163-171 kJ/mol. For the 
bromines, the range is 137-143 kJ/mol. Furthermore, activation of the iodine and bromine 
displays the effects of adding electron-withdrawing fluorine atoms to the ring. The charges on 
the non-activated iodobenzene and bromobenzene are 103 kJ/mol and 63 kJ/mol, respectively. 
The activated forms (substituting hydrogen atoms for fluorine atoms) are 166 kJ/mol and 143 
kJ/mol, respectively, Table 5.8. 
Table 5.8 Range of charges on the iodine and bromine XB donors. IPFB = 
iodopentafluorobenzene. BPFB = bromopentafluorobenzene. 
Iodine range Bromine range Activated Non-activated 
163-171 kJ/mol 137-143 kJ/mol 
Iodopentafluorobenzene 
(166 kJ/mol) 
Iodobenzene (103 kJ/mol) 
- - 
Bromopentafluorobenzene 
(143 kJ/mol) 
Bromobenzene (63 kJ/mol) 
 
The N-H proton on the pyrazole displays the highest positive electrostatic potential, and 
outranks all the XB donor molecules. For the pyrazole N-H, the values range from 225 kJ/mol to 
239 kJ/mol. In the ditopics, the values are even higher, ranging from 245 kJ/mol to 274 kJ/mol. 
The values in every case outrank the XB donor by ~80-100 kJ/mol, and the pyrazole N-H is 
expected to compete with the XB donors for the N(py) and N(pyz) XB acceptor sites. 
5.4.2 Does iodine show a higher success rate than bromine from the IR spectra results? 
From the results of the IR data, the supramolecular yield from the reactions between 
various pyrazole molecules and iodine and bromine donors is around the same percentage. For P, 
a 12.5% success rate was obtained for reactions with iodine donors; bromine donors were 
slightly higher at 16.7%. For DMP, a similar trend was observed; reactions with iodine donors 
gave a supramolecular yield of 37.5%, and those with bromine was slightly higher at 50%. For 
DMP-I, the reactions with iodine and bromine donors were essentially the same value. For the 
iodine donors, 37.5% supramolecular yield was obtained; for the bromine, 33.3% supramolecular 
yield was obtained.  
When a pyridine group is introduced as in 2, 3, and 4, the supramolecular yield increases 
for the iodine donors and stays about the same for the bromine donors. In the cases of 2,3,4, the 
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supramolecular yield jumps to 75%; the bromine values were 33.3%, 33.3%, and 50%, Table 
5.9. 
Table 5.9 Summary of supramolecular yields obtained from the screening experiments. 
Donors P DMP DMP-I 2 3 4 
Iodine 13% 38% 38% 75% 75% 75% 
Bromine 17% 50% 33% 33% 33% 50% 
 
The results show the halogen bonds to the pyrazole nitrogen atom are feasible, and the 
data also suggest that iodine···pyridine interactions are more favorable than bromine···pyridine 
interactions. A recent search using 1,4-DITFB and 1,4-DBTFB (as XB donors) and pyridine 
confirms that more structures containing iodine···pyridine interactions (as opposed to 
bromine···pyridine) are found, Table 5.10. 
Table 5.10 Summary of hits found in CSD. 
Interaction C-I···N(py) C-Br···N(py) 
# of CSD hits 50 11 
 
Moreover, pyrazole and pyrazole/pyridine ditopic acceptors display no activity with the 
unactivated XB donor molecules. The importance of activating the halogen is further highlighted 
by a recent CSD search which shows no hits for both 1,4-diiodobenzene and 1,4-
dibromobenzene, Table 5.11.  
Table 5.11 Summary of CSD results for co-crystals of 1,4-diiodobenzene vs. 1,4-
diiodotetrafluorobenzene. 
Name Activated Non-activated 
Structure 
  
# of CSD hits 112 0 
Structure 
  
# of CSD hits 18 0 
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5.4.3 Is the pyrazole nitrogen atom suitable for forming XB’s based on the single crystal 
results? 
From the single crystal data, it is clear that both nitrogen atoms, N(py) and N(pyz), can 
form XB interactions with activated iodine donor atoms. A summary of the observed synthons in 
the crystal structures is shown below, Table 5.12. 
Table 5.12 Summary of the observed interactions in the crystal structures. 
Synthons 
3 + 1,4-
DIOFB 
3 + 1,6-
DIPFH 
4 + 1,2-
DITFE 
4 + 1,4-
DIOFB 
2 + 1,4-
DITFB 
3 + 1,4-
DITFB 
4 + 1,4-
DITFB 
C-I···N(py) √ √  √   √ 
C-I···N(pyz)   √ √ √ √  
N-H···N(py)   √ √ √ √  
N-H···N(pyz) √ √  √   √ 
 
From the single crystal results, two groups of interactions are observed, and both contain 
hydrogen and halogen bonds. In group 1, an iodine atom interacts with a pyridine nitrogen atom, 
and a pyrazole N-H proton interacts with a pyrazole nitrogen atom. The two interactions together 
were observed in three structures (3/7). In group 2, an iodine atom interacts with a pyrazole 
nitrogen atom, and a pyrazole N-H proton interacts with a pyridine nitrogen atom. The two 
interactions together were also observed in three structures (3/7), Figure 5.12. 
 
Figure 5-12 The two groups of interactions observed in the crystals. 
 
It is therefore not surprising that in one crystal structure (1/7), both groups of synthons 
(Group 1 and Group 2) were observed. The results clearly show that the pyrazole nitrogen atom 
is a suitable XB acceptor, and can compete with the pyridine nitrogen atom for XB interactions. 
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When XB donors are combined with a molecule containing pyridine or pyrazole nitrogen 
acceptor atoms, then there is the likelihood of either interaction occurring.  
In support of these findings a recent example from the literature shows that both synthons 
can work together to form infinite chains.34 For example, the primary interactions observed in the 
crystal structure formed between 2-amino-3,5-dibromopyrazine and 1,4-diiodotetraflurobenzene 
displays an infinite chain assembled through the interplay of hydrogen and halogen bonds, 
Figure 5.13. 
 
Figure 5-13 The primary interactions observed in the crystals structure of 2-amino-3,5-
dibromopyrazine:1,4-DITFB displaying the hydrogen and halogen bonds.34  
 
In summary, 
I. Iodine based XB donors show an overall higher success rate than bromine donors 
for a reaction to occur when combined with a library of ditopic pyrazole/pyridine 
XB acceptors (52% vs. 36%); the pyrazole acceptors, P, DMP, and DMP-I, show 
little difference in supramolecular yield when combined with iodine or bromine 
XB donors.  
II. The pyrazole nitrogen atom, N(pyz), can act as a suitable XB acceptor. 
III. Two groups of synthons were observed in the crystal structures, Group 1 and 
Group 2, and both groups display an interplay of hydrogen and halogen bonds, 
respectively. 
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Can hydrogen-bonds (HB) and halogen-bonds (XB) Chapter 6 - 
influence nanoparticle assembly? 
 6.1 Introduction 
In Chapters 2-5, supramolecular synthons were used to construct multicomponent 
crystals. The synthons consisted of, in some cases, a combination of hydrogen and halogen 
bonds, both of which are considered fairly strong1 and directional2 ‘non-covalent’ electrostatic 
interactions which have been used for the assembly of small molecules.3 On the other hand, what 
if the same non-covalent interactions could be used to influence the assembly of much larger 
nanoparticles, Figure 6.1? 
 
 
Figure 6-1 Relative volumes of nanoparticles (~380nm
3
) compared to molecules 
(~20nm
3
) and coordination complexes (~80nm
3
). 
 
The first report of colloidal gold was made by Antonii4 and came in the early 17
th
 
century. However, the first synthesis was described by Faraday5 in the mid-19
th
 century, and 
describes the reduction of ionic gold to give nanoparticles.  
Since then, there has been an enormous amount of research on gold nanoparticles6 and 
nanomaterials in general.7 Nanomaterials are attractive for a number of reasons, and particular 
focus has been in their use in medicine8, environmental remediation9, and optical imaging.10 
Nanoparticles are made up of clusters of atoms which can be stabilized by long alkyl 
chains which can directly influence their solubility.11 The alkyl chains serve two purposes; first, 
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they contain an end which can coordinate to the surface of the nanoparticle. Second, they contain 
an ‘inert’ end which is typically a methyl group. The alkyl ligands can ‘interdigitate’, and space 
the particle cores, where the chains interact via van der Waals interactions, Figure 6.2. 
  
 
Figure 6-2 Arrangement of nanoparticles observed in dodecylamine functionalised gold 
nanoparticles. 
 
The properties of the nanoparticles and their ordered structures is dependent on both 
capping ligand12 and interparticle distance.13 Ligands containing thiol (R-SH) groups form 
stronger interactions with the gold surface compared to ligands containing an amine (R-NH2) 
group14, and ligands are designed with this in mind. Furthermore, capping ligands terminated 
with hydrogen bond donor (or acceptor) groups15 have been used for the construction of 
supramolecular assemblies. 
In 2010, the first report of a supramolecular assembly containing halogen bonds and gold 
nanoparticles was made. In this work, van der Boom et al.16 showed that N-oxide based ligands 
could be used to cap the nanoparticles and form halogen-bond interactions with bipyridyl-based 
organic linkers, Figure 6.3.  
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Figure 6-3 Ligands (1 and 2) and linkers (1 and 2) used in the halogen-bond assembly of 
nanoparticles.16  
 
When the XB donor particles were combined with the linkers, the particles formed dense 
aggregates and fractal networks. The results clearly demonstrated particle aggregation was 
influenced by XB interactions between XB donor (nanoparticle) and XB acceptor (bi-pyridyl 
linker). It is not surprising that C-I···N interactions were able to accomplish this goal, 
considering the number of examples in the CSD17 where this synthon is used to drive co-crystal 
formation.18 Thereofre, when designing new ligands for potential HB and XB interactions, the 
ligands should display the following features: 
 
I. An aliphatic chain terminated with a sulfur functionality (thiol or disulfide). 
II. A hydrogen bond (HB) and halogen-bond (XB) acceptor moiety (i.e. nitrogen). 
III. A HB and XB donor moiety (i.e. hydrogen and iodine, respectively). 
 
Data in the CSD has shown the versatility of pyridine as a halogen bond acceptor, and 
recent examples of XB to pyridine confirm the utility of this synthon.19 In addition to pyridine, 
imidazole-based acceptors have proven useful for forming XB with activated iodine atoms.20 
Therefore, capping ligands containing an imidazole–based acceptor (I) and activated iodine 
donor (II) were synthesized, Figure 6.4. 
113 
 
 
Figure 6-4 Target ligands (I) bis(8-imidazol-1-yloctyl)disulfide, (IM); (II) bis(8-
(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide, (XBD). 
 
Gold nanoparticles were synthesized using inverse micelle method following the method 
developed by Stoeva et. al.21 The particles were then subjected to digestive ripening22 
(purification procedure), and then a ligand exchange reaction. The exchange ligands were 
prepared using traditional organic synthetic techniques. The exchanged particles were washed 
with Toluene, dried, and re-dispersed in a polar solvent. The particles were then analysed using 
TEM and IR, and combined with other particles containing complementary functional groups. 
The combined samples were analyzed using TEM, dried and the residue analyzed using IR, 
Figure 6.5 
 
Figure 6-5 Flowchart for synthesis and characterization of gold nanoparticles. 
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This chapter will attempt to answer the following questions: 
I. Can suitable capping ligands for functionalizing the surface of gold nanoparticles 
be synthesized and used to make nanoparticles? 
II. Can nanoparticles be synthesized with HB and XB capping ligands?  
III. Can HB and XB interactions influence the assembly of nanoparticles?  
 
 6.2 Experimental 
6.2.1 Synthesis 
All chemicals were purchased from Sigma-Aldrich unless otherwise noted and used 
without further purification. Glassware used for making nanoparticles was cleaned using the 
following procedure: 1) Scrub with soap and water. 2) Rinse with aqua regia (3:1 HCl:HNO3). 3) 
Rinse with concentrated H2SO4. 4) Dip glassware in base bath. 5) Rinse with deionized water. 6) 
Oven dry overnight. Melting points were determined on a Fisher-Johns melting point apparatus 
and are uncorrected. UV-Vis data were collected on a Shimadzu UV-1650PC spectrophotometer. 
Infrared experiments were collected on a Thermo Scientific Nicolet 380 FT-IR using a ZnSe 
crystal. Transmission electron microscopy (TEM) images were collected using a Siemens CM-
100 electron microscope. IR Samples for TEM were prepared by placing a 2μL drop of the 
colloidal solution on a Formvar carbon copper grid on 400 mesh copper grids (FCF400-Cu) 
purchased from Electron Microscopy Sciences (Hatfield, PA). The grids were allowed to dry at 
room temperature (for toluene samples) and dried using a heat gun (for DMSO samples).  
6.2.1.1 Synthesis of 1-bromooctan-8-ol, 6.1 
 
To a round bottom flask, 1,8-octanediol (5.90g, 40.4mmol) and cyclohexane (105mL) 
were added. To the biphasic mixture, 47% HBr (27mL) was added and the mixture was stirred at 
reflux for 6 hours. Upon completion, the reaction mixture was cooled to room temperature, 
diluted with hexanes, and small amounts of aqueous Na2CO3 was added in small amounts until 
most of the bubbling ceased. The aqueous layer was separated, and the organic layer was washed 
with aqueous Na2CO3 (3 x 50mL), saturated NaCl (1 x50mL), dried over MgSO4 and reduced to 
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a light yellow oil (4.55g, 54%). 
1
H NMR (400 MHz, CDCl3)  ppm: 3.61 (t, J=6.64 Hz, 2H), 
3.39 (t, J=6.83 Hz, 2H), 1.70 - 1.91 (m, 4H), 1.53 (d, J=6.64 Hz, 4H), 1.20 - 1.45 (m, 4H), 
Figure A.22.  
6.2.1.2 Synthesis of 1-mercaptooctan-8-ol, 6.2 
 
To a round bottom flask, 6.1 (4.76g, 22.76mmol) and 200 proof ethanol (150mL) were 
added. To the solution, thiourea (3.59g, 47.12mmol) was added and the reaction refluxed for 3 
hours, at which point, 10% NaOH (75mL) was added and the reaction refluxed for a further 2 
hours. The reaction was cooled to room temperature and the pH adjusted to 2-3 with 2M HCl. 
The acidic solution was washed with dichloromethane (3 x 100mL), the organic extracts 
combined, dried over MgSO4 and reduced to an off-white solid/colorless oil (3.33g, 90%).  
1
H 
NMR (400 MHz, CDCl3)  ppm: 3.65 (t, J=6.44 Hz, 2H), 2.41 - 2.57 (m, 2H), 1.45 - 1.64 (m, 
4H), 1.17 - 1.43 (m, 8H), Figure A.23. 
6.2.1.3 Synthesis of bis(8-hydroxyoctyl)disulfide, 6.3 
 
To a round bottom flask, 6.2 (3.33g, 20.5mmol) and methanol (27mL) were added. Once 
in solution, a saturated solution of iodine (~30mL) was added drop wise until the solution 
remained orange/yellow. The reaction was then quenched with 10% NaHSO3 (75mL) and 
dichloromethane (75mL). The organic layer was extracted and the aqueous layer was washed 
with dichloromethane (4 x 50mL). All organic extracts were combined, dried over MgSO4 and 
reduced to a white solid. The solids were dried under high vacuum for 20 minutes. (2.41g, 73%). 
Mp: 41-44
o
C. 
1
H NMR (400 MHz, CDCl3)  ppm: 3.61 (t, J=6.44 Hz, 4 H), 2.66 (t, J=7.22 Hz, 
4H), 1.64 (dd, J=13.86, 6.83 Hz, 4H), 1.56 (br. s., 4H), 1.22 - 1.44 (m, 16H), Figure A.24. 
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6.2.1.4 Synthesis of bis(8-bromooctyl)disulfide, 6.4 
 
To a round bottom flask, 6.3 (3.11g, 9.64mmol) and cyclohexane (80mL) were added. 
Once in solution, 47% HBr (80mL) was added and the reaction refluxed for 24 hours, at which 
point a second portion of 47% HBr (80mL) was added and the reaction refluxed for an additional 
24 hours. Upon completion, the reaction was cooled to room temperature and diluted with 
hexanes (100mL). The aqueous layer was separated, and the organic layer was then washed with 
aqueous NaHCO3 (4 x 100mL) and saturated NaCl (1 x 100mL), separated, dried over MgSO4 
and reduced to a yellow liquid (2.81g, 65%). 
1
H NMR (400 MHz, CDCl3)  ppm: 3.41 (t, J=7.42 
Hz, 4H), 2.68 (t, J=6.83 Hz, 4H), 1.78 - 1.95 (m, 4H), 1.62 - 1.74 (m, 4H) 1.22 - 1.52 (m, 16H), 
Figure A.25. 
6.2.1.5 Synthesis of bis(8-imidazol-1-yloctyl)disulfide, 6.5 
 
To a round bottom flask, imidazole (2.20g, 32.3mmol) and dry THF (100mL) were 
added. Once in solution, NaOH pellets (3.18g, 79.5mmol) were added and the reaction stirred for 
2 hours at room temperature. Upon completion, 6.4 (3.48g, 7.76mmol) in dry THF (100mL) was 
added and the reaction stirred for 4 days at room temperature. Upon completion, H2O (100mL) 
was added to dissolve NaBr and NaOH and the aqueous layer was saturated with NaCl. The THF 
layer was extracted, dried over MgSO4 and reduced to a yellow oil. The yellow oil was dissolved 
in ethyl acetate (50mL) and washed with 1M NaOH(aq) (3 x 50mL). The organic layer was 
removed, dried over MgSO4 and reduced to a yellow oil (1.76g, 54%). 
1
H NMR (400 MHz, 
CDCl3)  ppm: 7.39 (s, 1H), 6.97 (s, 1H), 6.84 (s, 1H), 3.85 (t, J=7.03 Hz, 4H), 2.60 (t, J=7.03 
Hz, 4H), 1.47 - 1.81 (m, 8H), 1.04 - 1.41 (m, 16H), Figure A-26.; 
13
C NMR (δH; 100 MHz, 
CDCl3)  ppm: 137.18, 129.39, 118.97, 47.18, 39.14, 31.20, 29.25, 29.17, 29.09, 28.48, 26.62, 
Figure A-27.  
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6.2.1.6 Synthesis of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide, 6.6 
 
To a round bottom flask, 6.3 (0.211g, 0.654mmol) and Cs2CO3 (0.448g, 1.37mmol) were 
added. The mixture was warmed just above room temperature and stirred under nitrogen for two 
days, at which point Iodopentafluorobenzene (0.42g, 1.43mmol) was added. The reaction was 
stirred and heated around 40°C for an additional 24 hours, at which point a second addition of 
Cs2CO3 (0.460g, 1.41mmol) and Iodopentafluorobenzene (0.43g, 1.46mmol) were added. The 
reaction was stirred and heated for an additional 24 hours, then cooled to room temperature. The 
reaction was diluted with CH2Cl2 (40mL) and H2O (40mL). The aqueous layer was removed, and 
the organic layer was washed with aqueous NaCl (2 x 50mL), separated, dried over MgSO4 and 
reduced to a brown liquid. The product was isolated using a silica column packed with hexanes 
(100% hexanes as eluent) to give a yellow/orange oil (0.129g, 23%).
 1
H NMR (400 MHz, 
CDCl3)  ppm: 4.23 (t, J=6.44 Hz, 4H), 2.68 (t, J=7.42 Hz, 4H), 1.58 - 1.93 (m, 8H), 1.15 - 1.54 
(m, 16H), Figure A-28; 
19
F
 
NMR (δH; 376.3 MHz, CDCl3)  ppm: -154.78 (s, 4F), -121.99 (s, 
4F), Figure A-29.    
6.2.1.7 Synthesis of dodecylamine functionalised gold nanoparticles, 7 
To a clean, dry, 50mL Erlenmeyer flask, didodecyldimethylammonium bromide (DDAB) (1.62g, 
3.50mmol) was dissolved in freshly distilled toluene (10mL). AuCl3 (0.0340g, 0.112mmol) was 
added to the mixture and the resulting orange/red solution was sonicated until AuCl3 was 
dissolved. Argon was bubbled through the orange/red solution for one hour, at which point 
aqueous NaBH4 (36μL of a 9.4M solution) was added to the solution while stirring under Argon. 
The color changes from orange/red to yellow to deep red/purple. The red/purple solution was 
stirred under Argon for a further 15min to ensure complete reduction before being transferred 
into a clean, dry, 40ml vial. Dodecylamine (0.81g, 1474.37mmol) was then added neat to the vial 
and shaken vigorously for five minutes. The red/purple solution was diluted with absolute 
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ethanol (28mL) and shaken for one minute. The mixture settled overnight, and the 
ethanol/toluene/DDAB mixture was removed from the vial using a Pasteur pipette. The particles 
were covered in aluminum foil and dried under high vacuum for 15 minutes. 
6.2.1.8 Digestive ripening of gold nanoparticles, 8 
The dried particles, 7, were re-dissolved in dry toluene (15mL) to give a red/purple solution. The 
solution was transferred to a clean, dry 50mL round bottom flask containing a stirbar, and excess 
dodecylamine (0.81g, 1474.37mmol) was added. The reaction vessel was covered in aluminum 
foil (to block light) and heated to reflux under argon for 90 minutes. The red/purple solution was 
cooled to room temperature, transferred to a clean 40mL vial, and diluted with absolute ethanol 
(28mL). The mixture settled overnight, and the ethanol/toluene/Dodecylamine mixture was 
removed from the vial using a Pasteur pipette. The particles were covered in aluminum foil and 
dried under high vacuum for 15 minutes. The dried particles were stored under argon and 
wrapped in aluminum foil.  
6.2.1.9 Ligand exchange of gold nanoparticles, 9 
The dried, digestively ripened particles were redispersed in toluene (15mL) with 
sonication and heating. The exchange ligand (11-mercaptoundecanoic acid (MUA), 0.195g, 
0.893mmol; bis(8-imidazol-1-yloctyl)disulfide (IM) 0.377g, 0.893mmol; 1,2-bis(8-(2,3,5,6-
tetrafluoro-4-iodophenoxy)octyl)disulfide (XBD), 0.777g, 0.893mmol) was added to the solution 
neat and shaken for five minutes resulting in precipitation and a red/purple to purple color 
change. The particles were allowed to settle and the toluene was removed using a Pasteur pipette. 
The particles were washed with toluene (2x15mL) and dissolved in DMSO with heating and 
sonication. 
 
 6.3 Results 
6.3.1 TEM image of dodecylamine functionalized AuNP’s 
The TEM image of dodecylamine functionalized AuNP’s shows a nanoparticle 
superlattice containing particles uniform in size and shape. The particles are ~7-8nm in diameter 
with an average interparticle spacing of ~1.5nm, Figures 6.6 and 6.7. 
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Figure 6-6 TEM image of dodecylamine functionalized AuNP’s. (I) magnification = 
92,000x; scale = 100nm (II) magnification = 245,000x; scale = 20nm. 
 
 
Figure 6-7 Histogram of dodecylamine functionalized AuNP’s. 
 
6.3.2 TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s 
The TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s shows a 
fractal network. The particles are ~7-8 nm in diameter with an average interparticle spacing of 
~2nm, Figures 6.8 and 6.9. 
120 
 
 
Figure 6-8 TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s. 
(I) magnification = 92,000x; scale = 100nm (II) magnification = 130,000x; scale = 100nm. 
 
Figure 6-9 Histogram of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s.  
6.3.3 TEM image of bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s 
The TEM image of bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s shows 
clusters of particles. The particles are ~7-8 nm in diameter with an average interparticle spacing 
of ~1.7 nm, Figures 6.10 and 6.11. 
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Figure 6-10 TEM image of bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s. (I) 
magnification = 130,000x; scale = 100nm (II) magnification = 180,000x; scale = 20nm. 
 
Figure 6-11 Histogram of bis(8-imidazol-1-yloctyl)disulfide (DS-IM) functionalized 
AuNP’s.  
6.3.4 TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide functionalized 
AuNP’s 
The TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
functionalized AuNP’s shows clusters of particles. The particles are ~9-11 nm in diameter with 
an average interparticle spacing of ~1.7nm, Figures 6.12 and 6.13. 
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Figure 6-12 TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
functionalized AuNP’s. (I) magnification = 130,000x; scale = 100nm (II) magnification = 
180,000x; scale = 20nm. 
 
 
Figure 6-13 Histogram of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
functionalized AuNP’s. 
6.3.6 TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s + bis(8-
imidazol-1-yloctyl)disulfide functionalized AuNP’s 
The TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s 
combined with bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s shows fractal 
aggregates of particles, Figure 6.14. 
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Figure 6-14 TEM image of 11-mercaptoundecanoic acid (MUA) functionalized AuNP’s 
combined with bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s. (I) magnification = 
130,000x; scale = 100nm (II) magnification = 180,000x; (III) magnification = 64,000x; scale = 
20nm. 
6.3.7 TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide functionalized 
AuNP’s + bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s 
The TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide combined 
with bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s shows fractal aggregates of 
particles, Figure 6.15. 
124 
 
 
Figure 6-15 TEM image of bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
combined with bis(8-imidazol-1-yloctyl)disulfide functionalized AuNP’s. (I) magnification = 
130,000x; scale = 100nm (II) magnification = 180,000x; scale = 20nm. 
 
6.3.7 Determining nanoparticle ‘communication’ using infra-red (IR) spectroscopy 
IR spectroscopy is a useful tool for examining various spectroscopic bands from specific 
ligands and looking at shifts caused by nanoparticle interaction. In the system containing 11-
mercaptoundecanoic acid (MUA) gold nanoparticles combined with bis(8-imidazol-1-
yloctyl)disulfide gold nanoparticles, O-H···N hydrogen bonds are expected to form between the 
capping ligands. Two broad bands at 2500 cm
-1
 and 1900 cm
-1
, representing changes in the OH 
stretch, as well as changes in the position of the carbonyl C=O may give an indication that the 
ligands (and hence the nanoparticles) are interacting, Figure 6.16.  
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Figure 6-16 IR spectrum of 11-mercaptoundecanoic acid (MUA) capping ligand 
combined with bis(8-imidazol-1-yloctyl)disulfide capping ligand (green scan, top). AuIM 
nanoparticles combined with AuMUA nanoparticles showing the O-H···N hydrogen bonds (red 
scan, bottom). 
In the system containing bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
nanoparticles combined with bis(8-imidazol-1-yloctyl)disulfide nanoparticles, C-I···N halogen 
bonds are expected to form between the capping ligands, Figure 6.17. 
 
 
Figure 6-17 IR spectrum comparison of  bis(8-(2,3,5,6-tetrafluoro-4-
iodophenoxy)octyl)disulfide neat ligand (red scan, top) versus the combination of bis(8-
imidazol-1-yloctyl)disulfide and bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide gold 
nanoparticles (purple scan, bottom). 
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6.4 Discussion 
6.4.1 Examining the effect of digestive ripening 
Gold nanoparticles were heated in the presence of excess ligand (dodecylamine) to obtain 
well defined, monodisperse particles. Although the theory of how digestive ripening works23 is 
still a topic for debate, the utility of this method for the purification of dodecylamine gold 
nanoparticles is not. Pictures of the particles before and after digestive ripening, highlighting the 
differences in particle shape and arrangement is shown in Figure 6.18. 
 
Figure 6-18 TEM images of dodecylamine particles. (I) before digestive ripening and (II) 
after digestive ripening; magnification = 92,000x; scale = 100nm. 
 
6.4.2 Examining the effect of ligand exchange 
Ligand exchange reactions were carried out on digestively ripened dodecylamine gold 
nanoparticles (AuNH2) with the following ligands: 11-mercaptoundecanoic acid (MUA); bis(8-
imidazol-1-yloctyl)disulfide (IM); bis(8-(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide 
(XBD). The TEM images of the exchanged particles are shown in Figure 6.19. 
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Figure 6-19 TEM images of dodecylamine particles before and after ligand exchange. (I) 
11-mercaptoundecanoic acid (MUA); (II) bis(8-imidazol-1-yloctyl)disulfide (IM); (III) bis(8-
(2,3,5,6-tetrafluoro-4-iodophenoxy)octyl)disulfide (XBD); magnification = 92,000x; scale = 
100nm. 
6.4.3 Examining interparticle distances 
The distances between the as-prepared gold nanoparticles were measured and recorded in 
Table 6.1. The ligands containing an inert end (e.g methyl group) are expected to give a different 
spacing compared to a non-inert end (e.g carboxylic acid). Since the acid may be able to form a 
homomeric acid···acid interaction, the interparticle spacing is slightly larger compared to the 
methyl-terminated particles. The particles terminated with imidazole (AuIm) or 
tetrafluoroiodobenzene (AuXBD) give interparticle spacing distances that are intermediate from 
the methyl and carboxylic acid capped particles. A possible explanation for this is the ligands do 
not interdigitate like in AuNH2 since they are not intert and thus do not allow the ligands to 
interact as much. On the other hand, the particles are not capable of forming a homomeric tip to 
tip interaction, as may be the case in AuMUA. Therefore, their interparticle distance lies between 
the two values (1.5 and 2.0) of the AuNH2 and AuMUA, respectively, Table 6.1. 
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Table 6.1  Comparison of the interparticle distance between gold nanoparticles. 
AuNP AuNH2 AuMUA AuIM AuXBD 
AuMUA + 
AuIM 
AuXBD + 
AuIM 
Interparticle 
spacing 
~1.5 ~2.0 ~1.7 ~1.7 - - 
 
6.4.4 Examining interparticle ‘communication’ 
Interparticle communication was determined by examining both the TEM images and the 
IR spectrum obtained from the dried residue of the combination experiments between different 
nanoparticles. 
To determine if particle aggregation could take place by adding two different (i.e. 
different functionalized particles), AuIM was combined with AuNH2 to see if particle 
‘communication’ was taking place. The particles are not expected to communicate, since the 
capping ligands do not contain complementary functional groups. The images from the 
combination experiments are shown in Figure 6.20. 
 
 
Figure 6-20 TEM images of the combination of AuIM + AuNH2. 
 
As observed in the combination image, there is no evidence for the formation of dense 
clusters from the combination of the two non-complementary particles. This result eliminates the 
possibility of particle aggregation being caused by adding two separate particles together. 
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When AuNH2 is replaced with AuMUA, O-H···N hydrogen bonds form between the 
particles, resulting in dense aggregate formation. Furthermore, the IR data support the formation 
of HB between particles, as evidenced by the two broad stretches in the 2500 cm
-1
 and 1900 cm
-1
 
regions. 
To test the ability of halogen bonds to influence particle assembly, AuNH2 was replaced 
with AuXBD, which is capable of forming XB with AuIM. From the TEM images, dense 
clusters of particles formed, indicating the XB can influence the assembly of particle formation. 
The IR results show slight shifts in the bands, supporting the XB influence on particle assembly. 
To further support the observations, a comparison of Van der Boom’s XB assembly compared 
with our XB assembly is displayed in Figure 6.21. 
 
 
Figure 6-21 TEM images of Van der Boom’s particles (A) and the particles obtained in 
this study (B), both influenced by XB interactions. 
 
In summary, 
I. Suitable capping ligands for functionalizing the surface of gold nanoparticles have 
been synthesized. 
II. Nanoparticles can be made with hydrogen-bond (HB) and halogen-bond (XB) 
functionalized capping ligands. 
III. Relatively weak non-covalent interactions are capable of influencing the assembly 
of nanoparticles into clusters. 
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Appendix A - 
1
H, 
13
C and 
19
F NMR 
Figure A-1. 
1
H NMR of 1.Cl 
 
Figure A-2. 
1
H NMR of 1.Br 
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Figure A-3. 
1
H NMR of 1.I 
 
Figure A-4. 
1
H NMR of 2.Cl 
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Figure A-5. 
1
H NMR of 2.Br 
 
Figure A-6. 
1
H NMR of 2.I 
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Figure A-7. 
1
H NMR of 2 
 
Figure A-8. 
1
H NMR of 3 
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Figure A-9. 
1
H NMR of 4 
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Figure A-10. 
1
H NMR of IVa 
 
Figure A-11. 
13
C NMR of IVa 
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Figure A-12. 
1
H of IVb 
 
Figure A-13. 
13
C NMR of IVb 
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Figure A-14. 
1
H NMR of Va 
 
Figure A-15. 
13
C NMR of Va 
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Figure A-16. 
1
H NMR of Vb 
 
Figure A-17. 
13
C NMR of Vb 
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Figure A-18. 
1
H NMR of VI 
 
Figure A-19. 
13
C NMR of VI 
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Figure A-20. 
1
H NMR of VII 
 
Figure A-21. 
13
C NMR of VII 
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Figure A-22. 
1
H NMR of 6.1 
 
Figure A-23. 
1
H NMR of 6.2 
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Figure A-24. 
1
H NMR of 6.3 
 
Figure A-25. 
1
H NMR of 6.4 
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Figure A-26. 
1
H NMR of 6.5 
 
Figure A-27.
 13
C NMR of 6.5 
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Figure A-28.
 1
H NMR of 6.6 
 
Figure A-29.
 19
F NMR of 6.6 
 
